



(51) International Patent Classification:

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2017/036817

(22) International Filing Date:

09 June 2017 (09.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/348,009 09 June 2016 (09.06.2016) US

(71) Applicant: PELICAN THERAPEUTICS, INC.

[US/US]; 801 Capitola Drive, Bay 12, Durham, North Carolina 27713 (US).

(72) Inventors: SCHREIBER, Taylor H.; 3611 Rugby Rd,

Durham, North Carolina 27707 (US). HUTCHINS, Jeff T.; 15823 S. 4210 Rd., Claremore, Oklahoma 74017 (US).

(74) Agent: ALTIERI, Stephen, L.; Morgan, Lewis & Bockius

LLP, 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-TNFRSF25 ANTIBODIES

(57) Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.



WO 2017/214547 A1

ANTI-TNFRSF25 ANTIBODIES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of priority from U.S. Provisional Application Serial No. 62/348,009, filed on June 9, 2016.

5

TECHNICAL FIELD

This document relates to anti-TNFRSF25 antibodies, and to their use in research, therapeutic, and diagnostic purposes.

10

BACKGROUND

Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) is a TNF-receptor superfamily member that is preferentially expressed by activated and antigen-experienced T lymphocytes. TNFRSF25 is activated by its ligand, TL1A (also called TNFSF15), which is rapidly upregulated in antigen presenting cells and in some
15 endothelial cells following Toll-Like Receptor or Fc receptor activation. TNFRSF25 can stimulate NF-kappa B activity, and also can stimulate caspase activation to regulate cell apoptosis (Bodmer et al., *Immunity* 6(1):79-88, 1997; and Kitson et al., *Nature* 384(6607):372-375, 1996). The structural organization of the 393 amino acid long human TNFRSF25 protein is most homologous to TNF receptor 1 (TNFR1). The extracellular
20 domain of TNFRSF25 includes four cysteine-rich domains, and the cytoplasmic region contains a death domain known to signal apoptosis. Alternative splicing produces multiple distinct isoforms of TNFRSF25, most of which are potentially secreted molecules. Alternative splicing of the TNFRSF25 gene in B and T cells encounters a program change upon T-cell activation, which predominantly produces full-length,
25 membrane bound isoforms, and is thought to be involved in controlling lymphocyte proliferation induced by T-cell activation.

Activation of TNFRSF25 is dependent on previous engagement of the T cell receptor. After binding of TNARSF25 to TL1A, TNFRSF25 signaling increases the sensitivity of T cells to endogenous IL-2, and enhances T cell proliferation. Since

activation of TNFRSF25 is T cell receptor dependent, the activity of TNFRSF25 *in vivo* is specific to T cells that are encountering cognate antigen. At rest, and when there is no underlying autoimmunity, the majority of T cells that regularly encounter cognate antigen are FoxP3⁺ regulatory T cells. Stimulation of TNFRSF25, in the absence of any other
5 exogenous signals, stimulates highly specific proliferation of FoxP3⁺ regulatory T cells from a baseline of 8-10% of all CD4⁺ T cells to 35-40% of all CD4⁺ T cells, within five days (Schreiber et al., *J Clin Invest* 120(10):3629-3640, 2010). Therapeutic agonists of TNFRSF25 can be used to stimulate Treg expansion, which can reduce inflammation in experimental models of asthma, allogeneic solid organ transplantation, and ocular
10 keratitis (Schreiber et al., *supra*; Reddy et al., *J Virol* 86(19):10606-10620, 2012; and Wolf et al., *Transplantation* 94(6):569-574, 2012). Similarly, because TNFRSF25 activation is antigen dependent, costimulation of TNFRSF25 together with an autoantigen or with a vaccine antigen can lead to exacerbation of immunopathology or enhanced vaccine-stimulated immunity, respectively (Schreiber et al., *J Immunol*
15 189(7):3311-3318, 2010).

SUMMARY

This document is based, at least in part, on the development of antibodies targeted to particular epitopes within TNFSF25. In some embodiments, the antibodies can cross-
20 react between species. For example, in some embodiments, the present document provides antibodies that can bind to rodent and human TNFRSF25 polypeptides with K_d values that are within 100-fold (e.g., within 10-fold) of each other. In some cases, the antibodies described herein are capable of eliciting a signaling event that is consistent with the signaling activity of TL1A (e.g., rodent or human TL1A) binding to TNFRSF25.
25 In some embodiments, the antibodies are capable of binding to an epitope in the region of amino acids C48-L71 of human TNFRSF25. For example, the antibodies can bind specifically to an epitope in the region of amino acids P64-T69.

This document also is based, at least in part, on the development of affinity matured antibodies targeted to TNFRSF25. The affinity matured antibodies can have
30 increased affinity for TNFRSF25, as compared to the parental anti-TNFRSF25

antibody, or the affinity matured antibodies can have increased activity as compared to the parental anti-TNFRSF25 antibody, or the affinity matured antibodies can have both increased TNFRSF25 affinity and increased activity, as compared to the parental anti-TNFRSF25 antibody.

5 Thus, in a first aspect, this document features an anti-TNFRSF25 antibody or antigen binding fragment thereof. The antibody or antibody fragment can include (i) a heavy chain variable region containing heavy chain CDR1, CDR2, and CDR3 sequences, where the heavy chain CDR1 sequence is GFTFSNHDLN (SEQ ID NO:12), the heavy chain CDR2 sequence is YISSASGLISYADAVRG (SEQ ID NO:14); and the heavy
10 chain CDR3 sequence is DPAYTGLYALDF (SEQ ID NO:26); and (ii) a light chain variable region containing light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is TLSELNHWYTI (SEQ ID NO:25), the light chain CDR2 sequence is LKSDGSHSKGD (SEQ ID NO:21), and the light chain CDR3 sequence is CGAGYTLAGQYGV (SEQ ID NO:23).

15 The antibody or antibody fragment can include (i) a heavy chain variable region containing heavy chain CDR1, CDR2, and CDR3 sequences, where the heavy chain CDR1 sequence is GFTFSNHDLN (SEQ ID NO:12), the heavy chain CDR2 sequence is YISSASGLISYADAVRG (SEQ ID NO:14); and the heavy chain CDR3 sequence is DPPYSGLYALDF (SEQ ID NO:16); and (ii) a light chain variable region containing
20 light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is TLSELNHWYTI (SEQ ID NO:25), the light chain CDR2 sequence is LKSDGSHSKGD (SEQ ID NO:21), and the light chain CDR3 sequence is CGAGYTLAGQYGV (SEQ ID NO:23).

25 The antibody or antibody fragment can include (i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSNHDLN (SEQ ID NO:12), the heavy chain CDR2 sequence is YISSASGLISYADAVRG (SEQ ID NO:14); and the heavy chain CDR3 sequence is DPAYTGLYALDF (SEQ ID NO:26); and (ii) a light chain variable region comprising
30 light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is TLSELNHWYTI (SEQ ID NO:27), the light chain CDR2 sequence is

LKSDGSHSKGD (SEQ ID NO:21), and the light chain CDR3 sequence is CGAGYTLANQYGWV (SEQ ID NO:28).

The antibody or antigen binding fragment can further include variable region framework (FW) sequences juxtaposed between the CDRs according to the formula (FW1)-(CDR1)-(FW2)-(CDR2)-(FW3)-(CDR3)-(FW4), where the variable region FW sequences in the heavy chain variable region are heavy chain variable region FW sequences, and wherein the variable region FW sequences in the light chain variable region are light chain variable region FW sequences. The variable region FW sequences can be human. The antibody or antigen binding fragment can further contain human heavy chain and light chain constant regions. The constant regions can be selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4. The constant regions are IgG1 or IgG4. Tumor cell apoptosis in a subject can be increased following administration of the antibody or antigen binding fragment to the subject at a dose of about 0.1 mg/kg to about 50 mg/kg.

In another aspect, this document features a pharmaceutical composition containing a pharmaceutically acceptable carrier and an antibody or antigen binding fragment as disclosed herein.

In another aspect, this document features an article of manufacture containing the above pharmaceutical composition, and at least one additional agent for treating cancer.

The at least one additional agent can be an agent that targets CTLA-4, PD-1, PD-L1, LAG-3, Tim-3, TNFRSF4, TNFRSF9, TNFRSF18, CD27, CD39, CD47, CD73, or CD278, or can be an A2A receptor antagonist or a TGF-beta antagonist. The at least one additional agent can be one or more of a B7 family costimulatory molecule, a TNF receptor superfamily costimulatory molecule, a vaccine composition, or a chemotherapeutic agent. The at least one additional agent can include chimeric antigen receptor-transfected T cells or expanded tumor infiltrating lymphocytes for use in an adoptive T cell therapy *in vitro* or in a subject. The at least one additional agent can be used during the *in vitro* manufacturing process of an autologous T cell therapy.

In yet another aspect, this document features a method for treating a tumor in a subject, where the method includes administering to the subject an amount of the

composition described herein that is effective to induce apoptosis of TNFRSF25-expressing tumor cells in the tumor.

This document also features a method for stimulating proliferation of CD8⁺ T cells in a subject, where the method includes administering to the subject a therapeutically effective amount of a composition as described herein. The proliferation of CD8⁺ T cells can be increased by at least about 20% as compared to the baseline level of proliferation prior to the administering, as determined by flow cytometry analysis of antigen specific CD8⁺ T cells.

In addition, this document features a method of eliciting an immune response in a subject, where the method includes administering to the subject a therapeutically effective amount of a composition as described herein.

This document also features a method for stimulating proliferation of CD4⁺FoxP3⁺ regulatory T cells in a subject, where the method includes administering to the subject a therapeutically effective amount of a composition as described herein.

In another aspect, this document features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody or Fab fragment thereof, upon binding to TNFRSF25, elicits a signaling event that is consistent with a signaling even elicited by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids C48-L71 of human TNFRSF25. The antibody or fragment can bind to an epitope containing at least one of the following residues of TNFRSF25: C48, R49, G50, C51, P52, A53, G54, H55, Y56, L57, K58, A59, P60, C61, T62, E63, P64, C65, G66, N67, S68, T69, C70, or L71 of SEQ ID NO:1. Binding of the antibody or fragment to TNFRSF25 can block binding of TL1A to TNFRSF25. The antibody can be a humanized antibody or a human antibody. The antibody can be an IgG antibody of any subtype. The antibody or fragment can be capable of binding to mouse TNFRSF25, non-human primate TNFRSF25, and human TNFRSF25 with K_d values within 100-fold of the other.

In another aspect, this document features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody or Fab fragment thereof, upon binding to TNFRSF25, elicits a signaling event that is

characteristic of a signaling even elicited by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids P64-T69 of human TNFRSF25. The antibody or fragment can bind to an epitope containing at least one of the following residues of TNFRSF25: P64, C65, G66, N67, S68, or T69 of SEQ ID NO:1. Binding of the antibody or fragment to TNFRSF25 can block binding of TL1A to TNFRSF25. The antibody can be a humanized antibody or a human antibody. The antibody can be an IgG antibody of any subtype. The antibody or fragment can be capable of binding to mouse TNFRSF25, non-human primate TNFRSF25, and human TNFRSF25 with K_d values within 100-fold of the other.

In another aspect, this document features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having a sequence at least 80% identical to the sequence set forth in C48-L71 of SEQ ID NO:1. In some embodiments, the antibody can bind to an epitope having a sequence at least 90% identical to the sequence set forth in C48-L71 of SEQ ID NO:1, or to an epitope having a sequence at least 95%, at least 98%, or at least 99% identical to the sequence set forth in C48-L71 of SEQ ID NO:1.

In yet another aspect, this document features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having a sequence at least 85%, at least 90%, or at least 95% identical to the sequence set forth in P64-T69 of SEQ ID NO:1.

This document also features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with four or fewer amino acid substitutions. In some embodiments, the antibody can bind to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with three or fewer amino acid substitutions, with two or fewer amino acid substitutions, or with one amino acid substitution.

In another aspect, this document features an isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody

binds to an epitope having the sequence set forth in P64-T69 of SEQ ID NO:1, but with one amino acid substitution.

In still another aspect, this document features a method for inhibiting tumor growth in a mammal. The method can include administering to the mammal a composition containing a pharmaceutically acceptable carrier and a monoclonal antibody, or an Fab fragment thereof, that binds specifically to human TNFRSF25, wherein the antibody or Fab fragment thereof is capable of mimicking a signaling event stimulated by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids C48-L71 of human TNFRSF25. The antibody or fragment can bind to an epitope containing at least one of the following residues of TNFRSF25: C48, R49, G50, C51, P52, A53, G54, H55, Y56, L57, K58, A59, P60, C61, T62, E63, P64, C65, G66, N67, S68, T69, C70, or L71 of SEQ ID NO:1. The antibody or fragment can bind to an epitope containing at least one of the following residues of TNFRSF25: P64, C65, G66, N67, S68, or T69 of SEQ ID NO:1. Binding of the antibody or fragment to TNFRSF25 can block binding of TL1A to TNFRSF25. The antibody can be a humanized antibody or a human antibody. The antibody can be an IgG antibody of any subtype. The antibody or fragment can be capable of binding to mouse TNFRSF25, non-human primate TNFRSF25, and human TNFRSF25 with K_d values within 100-fold of the other.

In another aspect, this document features a pharmaceutical composition containing a pharmaceutically acceptable carrier and an isolated monoclonal antibody or Fab fragment as described herein. In addition, this document features the use of the pharmaceutical composition for treating cancer, infectious disease, or tissue graft in a patient.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the

present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1A is an amino acid sequence alignment of human TNFRSF25 (SEQ ID NO:2) with human TNFR1 (SEQ ID NO:3) and human Fas (SEQ ID NO:4), with which TNFRSF25 shares some homology. Sequence numbering starts at the N-terminus of the predicted mature protein. Locations of cysteine-rich regions I-IV, the transmembrane domain (TM), and the death domain (DD) are indicated. Residues that are identical between at least two of the sequences are bolded and underlined.

FIG. 1B shows two representative TNFRSF25 amino acid sequences from human (SEQ ID NOS:1 and 7), and representative TNFRSF25 amino acid sequences from mouse (SEQ ID NO:8), Rhesus Macaque (SEQ ID NO:9), and Cynomolgus Macaque (SEQ ID NO:10).

FIG. 2 is a diagram depicting the steps in a method for evaluating expression of various recombinant TNFRSF25 polypeptides.

FIG. 3 is a graph plotting expression levels for six recombinant TNFRSF25 polypeptides.

FIG. 4 is a diagram depicting the steps in a method for assessing the binding of a chimeric anti-TNFRSF25 antibody to recombinant TNFRSF25 polypeptides.

FIG. 5 is a graph plotting the binding of increasing amounts of a recombinant TNFRSF25 polypeptide to a chimeric anti-TNFRSF25 antibody.

FIG. 6 is a graph plotting the fold change in binding of various TNFRSF25 alanine mutants to an anti-TNFRSF25 antibody.

FIG. 7 is a diagram of the structure of TNFRSF25, indicating the positions of residues identified as being involved, or possibly being involved, in antibody binding.

FIG. 8 is a space-filling diagram of the TNFRSF25 structure, viewed from two sides, and indicating the positions of amino acids identified as being involved in antibody binding. "Hot spot" residues were identified as being in the domain between amino acids 48 and 71.

5 FIG. 9 is a graph plotting inhibition of binding of anti-TNFRSF25 antibodies to TNFRSF25 in the presence or absence of a TL1A-Ig fusion protein, or the inhibition of TL1A-Ig binding to TNFRSF25 in the presence or absence of an anti-TNFRSF25 antibody. Left columns: binding of an anti-TNFRSF25 antibody ("hamster parental") to recombinant human TNFRSF25 was completely inhibited in the presence of TL1A-Ig.
10 Center columns: binding of the TL1A-Ig fusion to recombinant human TNFRSF25 was completely inhibited in the presence of the parental anti-TNFRSF25 antibody. Right columns: binding of a humanized anti-TNFRSF25 antibody to recombinant human TNFRSF25 was completely inhibited in the presence of TL1A-Ig.

15 FIG. 10 is a graph plotting the binding of parent humanized anti-TNFRSF25 antibody and affinity matured clones to a TNFRSF25-Fc fusion protein.

 FIGS. 11A and 11B are graphs plotting caspase activity of parent anti-TNFRSF25 antibody, TL1A, and the indicated affinity matured clones. The affinity matured clones were in an IgG1 format.

20 FIG. 12 is a graph plotting caspase activity of parent anti-TNFRSF25 antibody, TL1A, and the indicated affinity matured clones. The affinity matured clones were in an IgG1 or IgG4 format, as indicated.

 FIG. 13A is a graph plotting fluorescence levels in competition assays in which ALEXAFLUOR® 647-labeled TL1A and various antibody competitors (4C12 parent and the M3, M4, and M5 affinity matured clones) were incubated with p815 cells expressing
25 TNFRSF25 (DR3). FIG. 13B is a graph plotting fluorescence levels in competition assays in which ALEXAFLUOR® 647-labeled 4C12 and various antibody competitors (4C12 parent, hIgG1, and the M3, M4, and M5 affinity matured clones) were incubated with p815 cells expressing TNFRSF25 (DR3).

DETAILED DESCRIPTION

This document is based, at least in part, on the development of antibodies targeted to particular epitopes within TNFRSF25. For example, this document provides antibodies that can bind to epitopes in the region of amino acids C48-L71 of human TNFRSF25. In some embodiments, the antibodies can bind to rodent and human TNFRSF25 polypeptides with K_d values that are within 100-fold (e.g., within 10-fold) of each other, and can be capable of mimicking the signaling activity of rodent or human TL1A binding to TNFRSF25. In some embodiments, the antibodies can bind to an epitope in the region of amino acids P64-T69, which is a conserved region of the polypeptide in placental mammals. Also provided herein are methods for using one or more of the antibodies provided herein, or compositions containing the one or more antibodies, to stimulate proliferation of T cells (e.g., human T cells, murine T cells, or macaque T cells), as well as methods for using the one or more antibodies or compositions to treat human cancer patients (e.g., by administering an amount of an anti-TNFRSF25 antibody that is effective to stimulate proliferation of CD8⁺ T cells).

This document also provides affinity matured humanized TNFRSF25 specific monoclonal antibodies, and antigen binding fragments of the affinity matured antibodies. Also provided herein are methods for using the affinity matured antibodies to, *inter alia*, stimulate proliferation of T cells (e.g., human T cells, including naturally-occurring tumor-reactive CD8⁺ T cells or CD4⁺FoxP3⁺ regulatory T cells, as well as murine T cells or macaque T cells), and methods for using affinity matured antibodies in the treatment of cancer and other disease states in which the expansion of T cells can have a beneficial effect (e.g., infectious disease, graft versus host disease, and autoimmune diseases). The methods can include, for example, administering an amount of an affinity matured antibody that is effective to stimulate proliferation of CD8⁺ T cells or the appropriate population of regulatory T cells.

A partial amino acid sequence for human TNFRSF25 is shown in FIG. 1, aligned with amino acid sequences for human TNFR1 and FAs. A representative full-length amino acid sequence of human TNFRSF25 is: MEQRPRGCAAVAAALLLVLLGARA

QGGTRSPRCD CAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPDITFLA
WENHHNSECARCOACDEQASOVALENC SAVADTRCGCKPGWFEVCOVSOCVSSSPF
YCOPCLDCGALHRHTRLLCSRRDITDCGTCLPGFYEHGDGCVSCTSTLGSCPERCA
AVCGWRQMFVWVQVLLAGLVVPLLLGATLTYYTYRHCWPHKPLVTADEAGMEAL
 5 TPPPATHL SPLDSAHTLL APPDSSEKICTVQLVGN SWTPGYPETQEALCPQVTWS
 WDQLPSRALGPAAPTLSPESPAGSPAMMLQPGPQLYDVMDAVPARRWKEFVR
 TLGLREAEIEAVEVEIGRFRDQQYEM LKRWRQQQPAGLGAVYAALERMGLDGC
 VEDLRSRLQRGP (SEQ ID NO:1)

As used herein, the term “antibody” refers to any immunoglobulin or antibody
 10 (e.g., human, hamster, feline, mouse, cartilaginous fish, or camelid antibodies), and any
 derivative or conjugate thereof, that specifically binds to an antigen. A wide variety of
 antibodies are known by those skilled in the art. Non-limiting examples of antibodies
 include monoclonal antibodies, polyclonal antibodies, humanized antibodies, multi-
 specific antibodies (e.g., bi-specific antibodies), single-chain antibodies (e.g., single-
 15 domain antibodies, camelid antibodies, and cartilaginous fish antibodies), chimeric
 antibodies, feline antibodies, and felinized antibodies. Monoclonal antibodies are
 homogeneous populations of antibodies to a particular epitope of an antigen. Polyclonal
 antibodies are heterogeneous populations of antibody molecules that are contained in the
 sera of the immunized animals. The term “antibody” also includes antibody derivatives
 20 and conjugates (e.g., an antibody conjugated to a stabilizing protein, a detectable moiety,
 or a therapeutic agent).

By “isolated” or “purified” with respect to a polypeptide (e.g., an antibody or a
 fragment thereof), it is meant that the polypeptide is separated to some extent from the
 cellular components with which would normally be found in nature (e.g., other
 25 polypeptides, lipids, carbohydrates, and nucleic acids). In some embodiments, an
 “isolated” polypeptide is one that is expressed and produced in an environment other than
 the environment in which the polypeptide would naturally expressed and produced. For
 example, a plant polypeptide is isolated when expressed and produced in bacteria or
 fungi. Similarly, a plant polypeptide is isolated when its gene coding sequence is

operably linked to a chimeric regulatory element and expressed in a tissue where the polypeptide is not naturally expressed.

An isolated polypeptide can yield a single major band on a non-reducing polyacrylamide gel. An isolated polypeptide can be at least about 75% pure (e.g., at least
5 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% pure). Isolated polypeptides can be obtained by, for example, extraction from a natural source, by chemical synthesis, or by recombinant production in a host cell or transgenic plant, and can be purified using, for example, affinity chromatography, immunoprecipitation, size exclusion chromatography, and ion exchange chromatography. The extent of purification can be measured using any
10 appropriate method, including, without limitation, column chromatography, polyacrylamide gel electrophoresis, or high-performance liquid chromatography.

An “antigen binding fragment” is any portion of a full-length antibody that contains at least one variable domain (e.g., a variable domain of a mammalian (e.g., feline, human, hamster, or mouse) heavy or light chain immunoglobulin, a camelid
15 variable antigen binding domain (VHH), or a cartilaginous fish immunoglobulin new antigen receptor (Ig-NAR) domain) that is capable of specifically binding to an antigen. Non-limiting examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments, diabodies, linear antibodies, and multi-specific antibodies formed from antibody fragments. Additional antibody fragments containing at least one camelid VHH
20 domain or at least one cartilaginous fish Ig-NAR domain include mini-bodies, micro-antibodies, subnano-antibodies, and nano-antibodies, and any of the other forms of antibodies described, for example, in U.S. Publication No. 2010/0092470.

An “Fv fragment” is the minimum antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy chain
25 variable domain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three complementary determining regions (CDRs) of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer. The term “complementary determining region” or “CDR” refers to a region within an immunoglobulin (a heavy or light chain immunoglobulin) that forms part of an antigen
30 binding site in an antibody or antigen binding fragment thereof. As is known in the art,

heavy chain and light chain immunoglobulins each contain three CDRs, referred to as CDR1, CDR2, and CDR3. In any antibody or antigen binding fragment, the three CDRs from the heavy chain immunoglobulin and the three CDRs from the light chain immunoglobulin together form an antigen binding site in the antibody or antigen binding
5 fragment thereof. The Kabat Database is one system used in the art to number CDR sequences present in a light chain immunoglobulin or a heavy chain immunoglobulin.

Collectively, the six CDR's confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDR's specific for an antigen) has the ability to recognize and bind the antigen, although usually
10 at a lower affinity than the entire binding site. The "Fab fragment" also contains the constant domain of the light chain and the first constant domain (C_H1) of the heavy chain. The "Fab fragment" differs from the "Fab' fragment" by the addition of a few residues at the carboxy terminus of the heavy chain C_H1 domain, including one or more cysteines from the antibody hinge region. The "F(ab')₂ fragment" originally is produced as a pair
15 of "Fab' fragments" which have hinge cysteines between them. Methods of preparing such antibody fragments, such as papain or pepsin digestion, are known to those skilled in the art. For example, F(ab')₂ fragments can be produced by pepsin digestion of an antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of F(ab')₂ fragments. In some cases, Fab expression libraries can be constructed. See, for
20 example, Huse et al., *Science*, 246:1275, 1989. Once produced, antibodies or fragments thereof can be tested for recognition of a TNFRSF25 polypeptide using standard immunoassay methods such as ELISA techniques, radioimmunoassays, and Western blotting. See, Short Protocols in Molecular Biology, Chapter 11, Green Publishing Associates and John Wiley & Sons, Ed. Ausubel et al., 1992.

25 An antibody can be of the IgA-, IgD-, IgE, IgG- or IgM-type, including IgG- or IgM-types such as, without limitation, IgG1-, IgG2-, IgG3-, IgG4-, IgM1- and IgM2-types. For example, in some cases, the antibody is of the IgG1-, IgG2- or IgG4- type.

In some embodiments, antibodies as provided herein can be fully human or humanized antibodies. By "human antibody" is meant an antibody that is encoded by a
30 nucleic acid (e.g., a rearranged human immunoglobulin heavy or light chain locus)

present in the genome of a human. In some embodiments, a human antibody can be produced in a human cell culture (e.g., feline hybridoma cells). In some embodiments, a human antibody can be produced in a non-human cell (e.g., a mouse or hamster cell line). In some embodiments, a human antibody can be produced in a bacterial or yeast cell.

5 Human antibodies can avoid certain problems associated with xenogeneic antibodies, such as antibodies that possess murine or rat variable and/or constant regions. For example, because the effector portion is human, it can interact better with other parts of the human immune system, e.g., to destroy target cells more efficiently by complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. In addition, the human immune system should not recognize the antibody as foreign. Further, half-life in human circulation will be similar to naturally occurring human antibodies, allowing smaller and less frequent doses to be given. Methods for preparing human antibodies are known in the art.

15 As used herein, the term “humanized antibody” refers to a human antibody that contains minimal sequence derived from non-human (e.g., mouse, hamster, rat, rabbit, or goat) immunoglobulin. Humanized antibodies generally are chimeric or mutant monoclonal antibodies from mouse, rat, hamster, rabbit or other species, bearing human constant and/or variable region domains or specific changes. In non-limiting examples, humanized antibodies are human antibodies (recipient antibody) in which hypervariable region (HVR) residues of the recipient antibody are replaced by HVR residues from a non-human species (donor) antibody, such as a mouse, rat, rabbit, or goat antibody having the desired specificity, affinity, and capacity. In some embodiments, Fv framework residues of the human immunoglobulin can be replaced by corresponding non-human residues. In some embodiments, humanized antibodies can contain residues that are not found in the recipient antibody or in the donor antibody. Such modifications can be made to refine antibody performance, for example.

25 In some embodiments, a humanized antibody can contain substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops (CDRs) correspond to those of a non-human immunoglobulin, while all or substantially all of the framework regions are those of a human immunoglobulin

sequence. A humanized antibody also can contain at least a portion of an immunoglobulin constant (Fc) region, typically that of a human immunoglobulin.

In some embodiments, a humanized antibody or antigen binding fragment as provided herein can have reduced or minimal effector function (e.g., as compared to
5 corresponding, non-humanized antibody), such that it does not stimulate effector cell action to the same extent that a corresponding non-humanized antibody would.

Techniques for generating humanized antibodies are well known to those of skill in the art. In some embodiments, controlled rearrangement of antibody domains joined through protein disulfide bonds to form new, artificial protein molecules or “chimeric”
10 antibodies can be utilized (Konieczny et al., *Haematologia (Budap.)* 14:95, 1981). Recombinant DNA technology can be used to construct gene fusions between DNA sequences encoding mouse antibody variable light and heavy chain domains and human antibody light and heavy chain constant domains (Morrison et al., *Proc Natl Acad Sci USA* 81:6851, 1984). For example, DNA sequences encoding antigen binding portions or
15 CDRs of murine monoclonal antibodies can be grafted by molecular means into DNA sequences encoding frameworks of human antibody heavy and light chains (Jones et al., *Nature* 321:522, 1986; and Riechmann et al., *Nature* 332:323, 1988). Expressed recombinant products are called “reshaped” or humanized antibodies, and contain the framework of a human antibody light or heavy chain and antigen recognition portions,
20 CDRs, of a murine monoclonal antibody.

Other methods for designing heavy and light chains and for producing humanized antibodies are described in, for example, U.S. Patent Nos. 5,530,101; 5,565,332; 5,585,089; 5,639,641; 5,693,761; 5,693,762; and 5,733,743. Yet additional methods for humanizing antibodies are described in U.S. Patent Nos. 4,816,567; 4,935,496;
25 5,502,167; 5,558,864; 5,693,493; 5,698,417; 5,705,154; 5,750,078; and 5,770,403, for example.

The term “single-chain antibody” refers to a single polypeptide that contains at least one variable binding domain (e.g., a variable domain of a mammalian heavy or light chain immunoglobulin, a camelid VHH, or a cartilaginous fish (e.g., shark) Ig-NAR

domain) that is capable of specifically binding to an antigen. Non-limiting examples of single-chain antibodies include single-domain antibodies.

As used herein, the term “single-domain antibody” refers to a polypeptide that contains one camelid VHH or at least one cartilaginous fish Ig-NAR domain that is capable of specifically binding to an antigen. Non-limiting examples of single-domain antibodies are described, for example, in U.S. Publication No. 2010/0092470.

An antibody or antigen binding fragment thereof “specifically binds” to a particular antigen, e.g., TNFRSF25, when it binds to that antigen in a sample, and does not recognize and bind, or recognizes and binds to a lesser extent, other molecules in the sample. In some embodiments, an antibody or an antigen binding fragment thereof can selectively bind to an epitope with an affinity (K_d) equal to or less than, for example, about 1×10^{-6} M (e.g., equal to or less than about 1×10^{-9} M, equal to or less than about 1×10^{-10} M, equal to or less than about 1×10^{-11} M, or equal to or less than about 1×10^{-12} M) in phosphate buffered saline. The ability of an antibody or antigen binding fragment to specifically bind a protein epitope can be determined using any of the methods known in the art or those methods described herein (e.g., by Biacore/Surface Plasmon Resonance). This can include, for example, binding to TNFRSF25 on live cells as a method to stimulate caspase activation in live transformed cells, binding to an immobilized target substrate including human TNFRSF25 fusion proteins as detected using an ELISA method, binding to TNFRSF25 on live cells as detected by flow cytometry, or binding to an immobilized substrate by surface plasmon resonance (including ProteOn).

Antibodies having specific binding affinity for TNFRSF25 can be produced using standard methods. For example, a TNFRSF25 polypeptide (e.g., having the sequence set forth in SEQ ID NO:1, SEQ ID NO:2, or a fragment of SEQ ID NO:1 or SEQ ID NO:2 that is at least six to ten amino acids in length) can be recombinantly produced, purified from a biological sample (e.g., a heterologous expression system), or chemically synthesized, and used to immunize host animals, including rabbits, chickens, mice, guinea pigs, or rats. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund’s adjuvant (complete and

incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin and dinitrophenol. Monoclonal antibodies can be prepared using a TNFRSF25 polypeptide and standard hybridoma technology. In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described by Kohler et al. (*Nature* 256:495, 1975), the human B-cell hybridoma technique of Kosbor et al. (*Immunology Today*, 4:72, 1983) or Cote et al. (*Proc. Natl. Acad. Sci. USA*, 80:2026, 1983), and the EBV-hybridoma technique described by Cole et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1983). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridoma producing the monoclonal antibodies can be cultivated *in vitro* and *in vivo*.

In some embodiments, a monoclonal anti-TNFRSF25 antibody as provided herein has a heavy chain variable region containing the amino acid sequence set forth in SEQ ID NO:5, but with one to 24 modifications (e.g., substitutions, additions, or deletions) such that the amino acid sequence is between 80% and 99.5% identical to SEQ ID NO:5. In some embodiments, a monoclonal anti-TNFRSF25 antibody as provided herein has a light chain variable region containing the amino acid sequence set forth in SEQ ID NO:6, but with one to 23 modifications (e.g., substitutions, additions, or deletions) such that the amino acid sequence is between 80% and 99.9% identical to SEQ ID NO:6. The sequences of SEQ ID NO:5 and SEQ ID NO:6 are as follows:

EVQLVESGGGLSQQPGNSLQLSCEASGFTFSNHDLNWVRQAPGKGLEWVAYISSAS
GLISYADAVRGRFTISRDNKNSLFLQMNNLKSEDTAMYCCARDPPYSGLYALDF
WGQGTQVTVSS (SEQ ID NO:5)

QPVLTQSPSASASLSGSKVLTCTLSSELSSYTIVWYQQRPKAPKYVMYLKSDGS
HSKGDGIPDRFSGSSSGAHRYLSISNVQSEDDATYFCGAGYTLAQYQGWVFGSG
TKVTVL (SEQ ID NO:6)

Thus, this document provides heavy chain variable region polypeptides containing the amino acid sequence set forth in SEQ ID NO:5, or an antigen binding fragment thereof, but with one to 24 sequence modifications, as well as polypeptides having at least about 80% (e.g., about 85%, about 90%, about 91%, about 92%, about 93%, about

94%, about 95%, about 96%, about 97%, about 98%, or about 99%) amino acid sequence identity to SEQ ID NO:5, or an antigen binding fragment thereof. In some embodiments, a heavy chain variable region polypeptide can contain 24 or less (e.g., 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, ten, nine, eight, seven, six, five, four, three, two, or one) amino acid substitution as compared to SEQ ID NO:5, or an antigen binding fragment thereof.

This document also provides light chain variable region polypeptides containing the amino acid sequence set forth in SEQ ID NO:6, or an antigen binding fragment thereof, but with one to 23 sequence modifications, as well as polypeptides having at least about 80% (e.g., about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) amino acid sequence identity to SEQ ID NO:6, or an antigen binding fragment thereof. In some embodiments, a light chain variable region polypeptide can contain 23 or less (e.g., 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, ten, nine, eight, seven, six, five, four, three, two, or one) amino acid substitutions as compared to SEQ ID NO:6, or an antigen binding fragment thereof.

This document also provides antibodies and antigen binding fragments that contain both a heavy chain variable region polypeptide and a light chain variable region polypeptide as disclosed herein. In some embodiments, for example, an antibody or antigen binding fragment can contain both a heavy chain variable region sequence comprising the amino acid sequence set forth in SEQ ID NO:5 with one to 24 amino acid substitutions (e.g., one to five, five to ten, ten to 15, 15 to 20, or 20 to 24 total amino acid substitutions), and a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:6 with one to 23 amino acid substitutions (e.g., one to five, five to ten, ten to 15, 15 to 20, or 20 to 23 total amino acid substitution). An amino acid substitution refers to the replacement of one amino acid residue with another in a peptide sequence.

In some embodiments, an anti-TNFRSF25 antibody or antigen-binding fragment thereof, as provided herein, can bind to an epitope of TNFRSF25 that has an amino acid sequence with at least 80% identity (e.g., at least 85%, at least 90%, or at least 95%

identity) to the sequence set forth in C48-L71 of SEQ ID NO:1. For example, in some cases an antibody or antigen-binding fragment thereof can bind to an epitope of TNFRSF25 that has the sequence set forth in C48-L71 of SEQ ID NO:1, but with four or fewer (e.g., three or fewer, or two or fewer) amino acid substitutions, or with one amino acid substitution.

In some embodiments, an anti-TNFRSF25 antibody or antigen-binding fragment thereof, as provided herein, can bind to an epitope of TNFRSF25 that has an amino acid sequence with at least 85% identity to the sequence set forth in P64-T69 of SEQ ID NO:1. For example, in some cases an antibody or antigen-binding fragment thereof can bind to an epitope of TNFRSF25 that has the sequence set forth in P64-T69 of SEQ ID NO:1, but with one amino acid substitution.

As described herein, a humanized monoclonal antibody against TNFRSF25, generated as described elsewhere (*see*, WO 2016/081455) was used in affinity maturation studies, leading to the identification of several heavy and light chain variable region CDR modifications that appeared to be associated with increased affinity and/or activity. Interestingly, however, and as discussed in Example 3 herein, the clones demonstrating the greatest binding affinity for TNFRSF25 were not always the clones that had the greatest activity over the parent antibody. For example, a clone identified herein as “M5” showed improved agonistic activity as determined by a caspase-3 release assay, but surprisingly, its binding to a TNFRSF25-Fc fusion protein was significantly weaker than most of the other clones identified by combinatorial library screening. An exception to this finding was a clone identified as “M4,” which exhibited both improved binding to TNFRSF25-Fc and improved agonistic activity as compared to the parent antibody.

Thus, in some cases, the antibodies provided herein can have increased binding affinity for TNFRSF25, increased agonistic activity (e.g., as determined by caspase-3 assay), or both increased affinity and activity, as compared to the parental humanized 4C12 antibody. By “increased” affinity or activity is meant an increase of at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) as compared to the affinity or agonist activity of humanized 4C12. Sequences of the variable regions of the 4C12 heavy and light chains are set forth herein in SEQ ID

NOS:5 and 6, respectively. The agonistic activity of an antibody can be assessed using, for example, a caspase-3 assay as described herein, or a TNFRSF25 receptor signaling assay as described elsewhere (*see, e.g., Bu et al., Bone 33(5):760-770, 2003*).

In some embodiments, therefore, this document provides heavy chain variable region polypeptides containing the CDR1 sequence set forth in SEQ ID NO:12, the CDR2 sequence set forth in SEQ ID NO:14, and a CDR3 sequence as set forth in any of SEQ ID NOS:16, 26, and 32. The polypeptide also can include variable region heavy chain framework (FW) sequences juxtaposed between the CDRs, according to the formula (FW1)-(CDR1)-(FW2)-(CDR2)-(FW3)-(CDR3)-(FW4), for example. In some embodiments, the FW sequences can be human sequences. In some embodiments, a heavy chain variable region polypeptide can include the FW1 sequence set forth in SEQ ID NO:11, the FW2 sequence set forth in SEQ ID NO:13, the FW3 sequence set forth in SEQ ID NO:15, and the FW4 sequence set forth in SEQ ID NO:17.

This document also provides light chain variable region polypeptides containing a CDR1 sequence as set forth in any of SEQ ID NOS:25, 27, and 29, the CDR2 sequence set forth in SEQ ID NO:21, and a CDR3 sequence as set forth in any of SEQ ID NOS:23, 28, and 30. The polypeptide also can include variable region light chain FW juxtaposed between the CDRs, according to the formula (FW1)-(CDR1)-(FW2)-(CDR2)-(FW3)-(CDR3)-(FW4). In some cases, the FW sequences can be human sequences. In some embodiments, a light chain variable region polypeptide can include the FW1 sequence set forth in SEQ ID NO:18, the FW2 sequence set forth in SEQ ID NO:20, the FW3 sequence set forth in SEQ ID NO:22, and the FW4 sequence set forth in SEQ ID NO:24.

This document also provides antibodies and antigen binding fragments that contain both a heavy chain variable region polypeptide and a light chain variable region polypeptide as disclosed herein. In some embodiments, for example, an antibody or antigen binding fragment can contain both a heavy chain variable region sequence having heavy chain CDR sequences as disclosed herein, and a light chain variable region sequence having light chain CDR sequences as disclosed herein. In some cases, the antibody is not a 4C12 antibody, such that it does not contain heavy chain variable region

CDRS as set forth in SEQ ID NOS:12, 14, and 16, and does not contain light chain variable region CDRs as set forth in SEQ ID NOS:19, 21, and 23.

In some embodiments, amino acid substitutions can be made by selecting conservative substitutions that do not differ significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. For example, naturally occurring residues can be divided into groups based on side-chain properties: (1) hydrophobic amino acids (norleucine, methionine, alanine, valine, leucine, and isoleucine); (2) neutral hydrophilic amino acids (cysteine, serine, and threonine); (3) acidic amino acids (aspartic acid and glutamic acid); (4) basic amino acids (asparagine, glutamine, histidine, lysine, and arginine); (5) amino acids that influence chain orientation (glycine and proline); and (6) aromatic amino acids (tryptophan, tyrosine, and phenylalanine). Substitutions made within these groups can be considered conservative substitutions. Non-limiting examples of conservative substitutions include, without limitation, substitution of valine for alanine, lysine for arginine, glutamine for asparagine, glutamic acid for aspartic acid, serine for cysteine, asparagine for glutamine, aspartic acid for glutamic acid, proline for glycine, arginine for histidine, leucine for isoleucine, isoleucine for leucine, arginine for lysine, leucine for methionine, leucine for phenylalanine, glycine for proline, threonine for serine, serine for threonine, tyrosine for tryptophan, phenylalanine for tyrosine, and/or leucine for valine. In some embodiments, an amino acid substitution can be non-conservative, such that a member of one of the amino acid classes described above is exchanged for a member of another class.

The percent sequence identity between a particular nucleic acid or amino acid sequence and a sequence referenced by a particular sequence identification number is determined as follows. First, a nucleic acid or amino acid sequence is compared to the sequence set forth in a particular sequence identification number using the BLAST 2 Sequences (Bl2seq) program from the stand-alone version of BLASTZ containing BLASTN version 2.0.14 and BLASTP version 2.0.14. This stand-alone version of BLASTZ can be obtained online at fr.com/blast or at ncbi.nlm.nih.gov. Instructions explaining how to use the Bl2seq program can be found in the readme file accompanying

BLASTZ. Bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. To compare two nucleic acid sequences, the options are set as follows: -i is set to a file containing the first nucleic acid sequence to be compared (e.g., C:\seq1.txt); -j is set to a file containing the second nucleic acid sequence to be compared (e.g., C:\seq2.txt); -p is set to blastn; -o is set to any desired file name (e.g., C:\output.txt); -q is set to -1; -r is set to 2; and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two sequences: C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastn -o c:\output.txt -q -1 -r 2. To compare two amino acid sequences, the options of Bl2seq are set as follows: -i is set to a file containing the first amino acid sequence to be compared (e.g., C:\seq1.txt); -j is set to a file containing the second amino acid sequence to be compared (e.g., C:\seq2.txt); -p is set to blastp; -o is set to any desired file name (e.g., C:\output.txt); and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two amino acid sequences: C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastp -o c:\output.txt. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.

Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence (e.g., SEQ ID NO:1), or by an articulated length (e.g., 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, an amino acid sequence that has 110 matches when aligned with the sequence set forth in SEQ ID NO:1 is 90.9 percent identical to the sequence set forth in SEQ ID NO:1 (i.e., $110 \div 121 \times 100 = 90.9$). It is noted that the percent sequence identity value is rounded to the nearest tenth. For

example, 75.11, 75.12, 75.13, and 75.14 is rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 is rounded up to 75.2. It also is noted that the length value will always be an integer.

In addition, this document also provides pharmaceutical compositions that contain
5 an antibody or antigen binding fragment as described herein, in combination with a pharmaceutically acceptable carrier. A “pharmaceutically acceptable carrier” (also referred to as an “excipient” or a “carrier”) is a pharmaceutically acceptable solvent, suspending agent, stabilizing agent, or any other pharmacologically inert vehicle for delivering one or more therapeutic compounds to a subject (e.g., a mammal, such as a
10 human, non-human primate, dog, cat, sheep, pig, horse, cow, mouse, rat, or rabbit), which is nontoxic to the cell or subject being exposed thereto at the dosages and concentrations employed. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when
15 combined with one or more of therapeutic compounds and any other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers that do not deleteriously react with amino acids include, by way of example and not limitation: water, saline solution, binding agents (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose), fillers (e.g., lactose and other sugars, gelatin, or calcium sulfate),
20 lubricants (e.g., starch, polyethylene glycol, or sodium acetate), disintegrates (e.g., starch or sodium starch glycolate), and wetting agents (e.g., sodium lauryl sulfate). Pharmaceutically acceptable carriers also include aqueous pH buffered solutions or liposomes (small vesicles composed of various types of lipids, phospholipids and/or surfactants which are useful for delivery of a drug to a mammal). Further examples of
25 pharmaceutically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine, monosaccharides, disaccharides, and other
30 carbohydrates including glucose, mannose or dextrans, chelating agents such as EDTA,

sugar alcohols such as mannitol or sorbitol, salt-forming counterions such as sodium, and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

Pharmaceutical compositions can be formulated by mixing one or more active agents with one or more physiologically acceptable carriers, diluents, and/or adjuvants, and optionally other agents that are usually incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A pharmaceutical composition can be formulated, e.g., in lyophilized formulations, aqueous solutions, dispersions, or solid preparations, such as tablets, dragees or capsules. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (18th ed, Mack Publishing Company, Easton, PA (1990)), particularly Chapter 87 by Block, Lawrence, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies as described herein, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See, also, Baldrick, *Regul Toxicol Pharmacol* 32:210-218, 2000; Wang, *Int J Pharm* 203:1-60, 2000; Charman *J Pharm Sci* 89:967-978, 2000; and Powell et al. *PDA J Pharm Sci Technol* 52:238-311, 1998), and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

Pharmaceutical compositions include, without limitation, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, for example, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w/o) or oil-in-water (o/w)

variety. Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of solubilization, absorption, and bioavailability.

Compositions and formulations can contain sterile aqueous solutions, which also
5 can contain buffers, diluents and other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers). Compositions additionally can contain other adjunct components conventionally found in pharmaceutical compositions. Thus, the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local
10 anesthetics or anti-inflammatory agents, or additional materials useful in physically formulating various dosage forms of the compositions provided herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. Furthermore, the composition can be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic
15 pressure, buffers, colorings, flavorings, and aromatic substances. When added, however, such materials should not unduly interfere with the biological activities of the polypeptide components within the compositions provided herein. The formulations can be sterilized if desired.

In some embodiments, a composition containing an antibody or antigen binding
20 fragment as provided herein can be in the form of a solution or powder with or without a diluent to make an injectable suspension. The composition may contain additional ingredients including, without limitation, pharmaceutically acceptable vehicles, such as saline, water, lactic acid, mannitol, or combinations thereof, for example.

Any appropriate method can be used to administer an antibody or antigen binding
25 fragment as described herein to a mammal. Administration can be, for example, parenteral (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip). Administration can be rapid (e.g., by injection) or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations). In some embodiments, administration can be topical (e.g.,
30 transdermal, sublingual, ophthalmic, or intranasal), pulmonary (e.g., by inhalation or

insufflation of powders or aerosols), or oral. In addition, a composition containing an antibody or antigen binding fragment as described herein can be administered prior to, after, or in lieu of surgical resection of a tumor.

A composition containing an anti-TNFRSF25 antibody or antigen binding
5 fragment can be administered to a mammal in any appropriate amount, at any appropriate frequency, and for any appropriate duration effective to achieve a desired outcome. For example, an anti-TNFRSF25 antibody or antigen binding fragment can be administered to a subject in an amount effective to stimulate proliferation of T cells *in vitro* or *in vivo* (e.g., human, murine, hamster, or macaque T cells, including CD8+ T cells and/or
10 CD4+FoxP3+ regulatory T cells), to stimulate apoptosis of tumor cells that express TNFRSF25, to reduce tumor size, or to increase progression-free survival of a cancer patient. In some embodiments, an anti-TNFRSF25 antibody or antigen binding fragment can be administered at a dosage of about 0.1 mg/kg to about 10 mg/kg (e.g., about 0.1 mg/kg to about 1 mg/kg, about 1 mg/kg to about 5 mg/kg, or about 5 mg/kg to about 10
15 mg/kg), and can be administered once every one to three weeks (e.g., every week, every 10 days, every two weeks, or every three weeks).

Administration to a subject of an antibody or antigen binding fragment as provided herein can result in increased numbers of T cells (e.g., naturally-occurring tumor-reactive CD8+ T cells or CD4+FoxP3+ regulatory T cells) that can exert anti-
20 cancer effects against cancer cells present within the mammal. Thus, this document also provides methods for stimulating proliferation of T cells in a subject, by administering to the subject an antibody, antigen-binding fragment, or composition as disclosed herein. In some cases, a composition containing an anti-TNFRSF25 antibody or antigen binding fragment as described herein can be administered to a subject in an amount effective to
25 increase proliferation of T cells (e.g., by at least about 10 percent, about 20 percent, about 25 percent, about 50 percent, about 60 percent, about 70 percent, about 75 percent, about 80 percent, about 90 percent, about 100 percent, or more than 100 percent), as compared to the “baseline” level of T cell proliferation in the subject prior to administration of the composition, or as compared to the level of T cell proliferation in a control subject or
30 population of subjects to whom the composition was not administered. The T cells can

be, for example, CD8+ T cells, or CD4+FoxP3+ regulatory T cells. Any suitable method can be used to determine whether or not the level of T cell proliferation is increased in the subject. Such methods can include, without limitation, flow cytometry analysis of antigen specific T cells (e.g., flow cytometry analysis of the proportion of antigen
5 specific CD8+ T cells as a fraction of the total CD8+ T cell pool), analysis of cell proliferation markers (e.g., expression of Ki67) in CD8+ T cells, increased counts of CD8+ T cells, or increased proportions of individual TCR sequences of a particular clone of CD8+ T cells.

This document also provides methods for promoting apoptosis of TNFRSF25-
10 expressing tumor cells in a subject, by treating the subject with an antibody, antigen-binding fragment, or composition as described herein. In some cases, a composition containing an antibody or antigen binding fragment as provided herein can be administered to a subject (e.g., a cancer patient) in an amount effective to increase apoptosis of TNFRSF25-expressing tumor cells (e.g., by at least about 10 percent, about
15 20 percent, about 25 percent, about 50 percent, about 60 percent, about 70 percent, about 75 percent, about 80 percent, about 90 percent, about 100 percent, or more than 100 percent), as compared to the “baseline” level of tumor cell apoptosis in the subject prior to administration of the composition, or as compared to the level of tumor cell apoptosis in a control subject or population of subjects to whom the composition was not
20 administered. Any suitable method can be used to determine whether or not the level of tumor cell apoptosis is increased in the subject. This can include, for example, radiologic techniques such as CT or MRI, with or without contrast that indicates the presence of a necrotic or apoptotic tumor, biopsy of a tumor sample indicating increased tumor cell death, caspase induction within tumor cells, elimination of detectable tumor lesions by
25 radiologic, or surgical or physical examination.

Methods for treating a subject (e.g., a human patient) with cancer, including solid tumors and leukemias/lymphomas) also are provided herein. In some cases, a composition containing an antibody or antigen binding fragment as described herein can be administered to a subject having cancer in an amount effective to reduce the
30 progression rate of the cancer (e.g., by at least about 10 percent, about 20 percent, about

25 percent, about 50 percent, about 60 percent, about 70 percent, about 75 percent, about 80 percent, about 90 percent, or more than 90 percent), as compared to the rate of cancer progression in the subject prior to administration of the composition, or as compared to the rate of cancer progression in a control subject or population of subjects to whom the composition was not administered. In some embodiments, the progression rate can be reduced such that no additional cancer progression is detected. Any appropriate method can be used to determine whether or not the progression rate of cancer is reduced. For skin cancer (e.g., melanoma), for example, the progression rate can be assessed by imaging tissue at different time points and determining the amount of cancer cells present. The amounts of cancer cells determined within tissue at different times can be compared to determine the progression rate. After treatment as described herein, the progression rate can be determined again over another time interval. In some cases, the stage of cancer after treatment can be determined and compared to the stage before treatment to determine whether or not the progression rate has been reduced.

A composition containing an antibody or antigen binding fragment as described herein also can be administered to a subject having cancer under conditions where progression-free survival is increased (e.g., by at least about 10 percent, about 20 percent, about 25 percent, about 50 percent, about 60 percent, about 70 percent, about 75 percent, about 80 percent, about 90 percent, about 100 percent, or more than 100 percent), as compared to the median progression-free survival of corresponding subjects having untreated cancer or the median progression-free survival of corresponding subjects having cancer and treated with other therapies (e.g., chemotherapeutic agents alone). Progression-free survival can be measured over any length of time (e.g., one month, two months, three months, four months, five months, six months, or longer).

An effective amount of a composition containing a molecule as provided herein can be any amount that has a desired effect (e.g., stimulates proliferation of CD8⁺ T cells, stimulates apoptosis of TNFRSF25-expressing tumor cells, stimulates or elicits an immune response in a subject, reduces tumor size, reduces the progression rate of cancer, increases progression-free survival of a cancer patient, or increases the median time to progression without producing significant toxicity). Optimum dosages can vary

depending on the relative potency of individual polypeptides (e.g., antibodies and antigen binding fragments), and can generally be estimated based on EC₅₀ found to be effective in in vitro and in vivo animal models. Typically, dosage is from 0.01 µg to 100 g per kg of body weight. For example, an effective amount of an antibody or antigen binding
5 fragment can be from about 0.1 mg/kg to about 50 mg/kg (e.g., about 0.4 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, or about 50 mg/kg), or any range there between, such as about 0.1 mg/kg to about 10 mg/kg, about 0.4 mg/kg to about 20 mg/kg, about 2 mg/kg to about 30 mg/kg, or about 5 mg/kg to about 40 mg/kg. If a particular subject fails to respond to a particular
10 amount, then the amount of the antibody or antigen binding fragment can be increased by, for example, two fold. After receiving this higher concentration, the subject can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustments made accordingly. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the subject's response to
15 treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, and severity of the cancer may require an increase or decrease in the actual effective amount administered.

The frequency of administration can be any frequency that, for example,
20 stimulates proliferation of CD8⁺ T cells, stimulates apoptosis of TNFRSF25-expressing tumor cells, reduces tumor size, reduces the progression rate of cancer, increases progression-free survival of a cancer patient, or increases the median time to progression without producing significant toxicity. For example, the frequency of administration can be once or more daily, biweekly, weekly, monthly, or even less. The frequency of
25 administration can remain constant or can be variable during the duration of treatment. A course of treatment can include rest periods. For example, a composition containing an antibody or antigen binding fragment as provided herein can be administered over a two-week period followed by a two-week rest period, and such a regimen can be repeated multiple times. As with the effective amount, various factors can influence the actual
30 frequency of administration used for a particular application. For example, the effective

amount, duration of treatment, use of multiple treatment agents, route of administration, and severity of the cancer may require an increase or decrease in administration frequency.

An effective duration for administering a composition provided herein can be any duration that stimulates proliferation of CD8⁺ T cells, stimulates apoptosis of TNFRSF25-expressing tumor cells, reduces tumor size, reduces the progression rate of cancer, increases progression-free survival of a cancer patient, or increases the median time to progression without producing significant toxicity. Thus, an effective duration can vary from several days to several weeks, months, or years. In general, the effective duration for the treatment of cancer can range in duration from several weeks to several months. In some cases, an effective duration can be for as long as an individual subject is alive. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, route of administration, and severity of the cancer.

After administering a composition as provided herein to a cancer patient, the patient can be monitored to determine whether or not the cancer was treated. For example, a subject can be assessed after treatment to determine whether or not the progression rate of the cancer has been reduced (e.g., stopped). Any method, including those that are standard in the art, can be used to assess progression and survival rates.

A method for using an antibody or antigen binding fragment as provided herein can be combined with known methods of treatment for cancer, for example, either as combined or additional treatment steps, or as additional components of a therapeutic formulation. For example, enhancing a host's immune function can be useful to combat tumors. Methods can include, without limitation, APC enhancement, such as by injection into a tumor of DNA encoding foreign MHC antigens (including tumor antigens, mutation derived antigens, or other antigens), or transfecting biopsied tumor cells with genes that increase the probability of immune antigen recognition (e.g., immune stimulatory cytokines, GM-CSF, or co-stimulatory molecules B7.1, B7.2) of the tumor. Other methods can include, for example, solubilization of specific tumor antigens into

depot or sustained release preparations, transfection of allogeneic tumor cells with adjuvant proteins or antigen carrier proteins, transfection of allogeneic tumor cells with immune stimulatory proteins such as alpha galactosylceramide, incorporation of specific tumor antigens into virus-derived vaccine regimens, incorporation of specific tumor antigens into *Listeria* derived vaccine regimens, adoptive cellular immunotherapy (including chimeric antigen receptor transfected T cells), or treatment with activated tumor-specific T-cells (including *ex vivo* expanded tumor infiltrating lymphocytes). Adoptive cellular immunotherapy can include isolating tumor-infiltrating host T-lymphocytes and expanding the population *in vitro* (e.g., by stimulation with IL-2). The T-cells then can be re-administered to the host. Other treatments that can be used in combination with an antibody or antigen-binding fragment as provided herein include, for example, radiation therapy, chemotherapy, hormonal therapy, and the use of angiogenesis inhibitors. Further combination partners that may be useful include checkpoint inhibitors (e.g., anti-PD1/L1, anti-CTLA-4, anti-LAG3, anti-B7-H3, anti-B7-H4, anti-TIM3, anti-TIGIT, anti-CD47, anti-TMIGD2, anti-BTLA, anti-CEACAM, or anti-GARP), other costimulatory antibodies (e.g., anti-OX40, anti-ICOS, anti-CD137, anti-GITR, or anti-CD40), cancer vaccines (e.g., virus based vaccines, peptide vaccines, whole-cell vaccines, or RNA based vaccines), and targeted agents [e.g., HERCEPTIN® (trastuzumab), TARCEVA® (erlotinib), AVASTIN® (bevacizumab), or IMBRUVICA® (ibrutinib)].

Thus, in some embodiments, an anti-TNFRSF25 antibody or antigen binding fragment can be used in combination with one or more additional monoclonal antibodies that inhibit binding of PD-L1 to PD-1, inhibit binding of CTLA-4 to CD80 or CD86, or activate signaling via the TNFRSF4, TNFRSF9, or TNFRSF18 pathways, for example. This also can include administration with another antibody, fusion protein, or small molecule that binds a specific target on a tumor cell (e.g., combinations with monoclonal antibodies that bind targets such as CD20, Her2, EGFRvIII, DR4, DR5, VEGF, CD39, and CD73). An anti-TNFRSF25 antibody or antigen binding fragment also can be used in combination with a cancer vaccine approach to enhance the activation of tumor antigen specific T cells in a cancer patient. In addition, an anti-TNFRSF25 antibody or antigen

binding fragment can be used after administration of autologous or allogeneic T or NK cells engineered to express a chimeric T cell receptor that recognizes a specific tumor antigen. Further, an anti-TNFRSF25 antibody or antigen binding fragment can be used in combination with specific chemotherapy or radiation therapy strategies as a method to expand tumor specific T cells and enhance the activity of either approach as a monotherapy in a cancer patient.

When one or more conventional therapies are combined with treatment using an anti-TNFRSF25 antibody or antigen binding fragment as provided herein for treating cancer, for example, the conventional therapy(ies) can be administered prior to, subsequent to, or simultaneously with administration of the anti-TNFRSF25 antibody or antigen binding fragment. For example, a PD-1 blocking antibody can be administered to a patient prior to administration of a TNFRSF25 agonist antibody. Such a regimen can be cycled over a period of weeks, months, or years, for example. Alternatively, a PD-1 blocking antibody can be administered at the same time or after administration of a TNFRSF25 agonist antibody. Such a regimen also can be cycled over a period of weeks, months, or years. In some embodiments, combination therapies that are repeatedly administered over a period of time can include two or more of the above administration strategies.

In some embodiments, an anti-TNFRSF25 antibody or antigen binding fragment as provided herein can be used during an *in vitro* assay or manufacturing process as a method for stimulating proliferation of tumor infiltrating lymphocytes isolated from a cancer patient, or to stimulate proliferation of chimeric antigen receptor expressing T cells being expanded *in vitro* and intended for subsequent infusion for the treatment of a cancer patient.

Also provided herein are articles of manufacture containing an antibody or antigen binding fragment as described herein, or a pharmaceutical composition containing the antibody or antigen binding fragment. The antibody or pharmaceutical composition can be within a container (e.g., a bottle, vial, or syringe). The article of manufacture also can include a label with directions for reconstituting and/or using the antibody, antigen binding fragment, or composition. In some embodiments, an article of

manufacture can include one or more additional items (e.g., one or more buffers, diluents, filters, needles, syringes, and/or package inserts with further instructions for use). An article of manufacture also can include at least one additional agent for treating cancer. For example, an article of manufacture as provided herein can contain an agent that

5 targets CTLA-4, PD-1, PD-L1, LAG-3, Tim-3, TNFRSF4, TNFRSF9, TNFRSF18, CD27, CD39, CD47, CD73, or CD278. In some embodiments, an article of manufacture can contain an A2A receptor antagonist or a TGF-beta antagonist. In some embodiments, an article of manufacture can include a B7 family costimulatory molecule (e.g., CD28 or CD278) or a TNF receptor superfamily costimulatory molecule (e.g., TNFRSF4,

10 TNFRSF9, or TNFRSF18), a chemotherapeutic agent, or an anti-tumor vaccine composition.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

15 EXAMPLES

Example 1 – Epitope Mapping

Several TNFRSF25 expression constructs were prepared. These included either the entire extracellular domain (ECD) extending from the Gln at position 25 (Q25) to the Phe at position 201 (F201), or a soluble splice variant extending from Q25 to the Thr at

20 position 181 (T181). The constructs also included various tags, including 6His, hFc-6His, and mFc-His. Six constructs (TABLE 1) were transfected into 293F cells, and their expression levels were measured as depicted in FIG. 2.

TABLE 1

Sample	Protein
Whis	W381-hPro1.ECD-W.His
WmFchis	W381-hPro1.ECD-W.mFcHis
WhFchis	W381-hPro1.ECD-W.hFcHis
Mhis	W381-hPro1.ECD-M.His
MmFchis	W381-hPro1.ECD-M.mFcHis
MhFchis	W381-hPro1.ECD-M.hFcHis
NC	Negative Control (plasfect)

W = extracellular domain (QGGT GWRQMF)

M = soluble splice variant (QGGT SCPT)

5 Of the constructs tested, W381-hPro1.ECD-M.mFcHis demonstrated the highest expression (FIG. 3). This version of TNFRSF25 therefore was chosen as the backbone for alanine scanning-based epitope mapping.

Seventy-three alanine mutants were generated, and their expression was measured as described above. The mutants were divided into five groups based on their expression
 10 levels (TABLES 2A and 2B), and were used for binding activity analysis.

TABLE 2A

Expression level	# of Mutants
>1500	27
1000-1500	14
600-1000	17
300-600	14
<300	1
Total	73

To identify the epitope of TNFRSF25 recognized by the antibody, binding of the antibody to TNFRSF25 muteins was then evaluated using the steps depicted in FIG. 4. Specifically, studies were conducted to assess the binding of a chimeric antibody, W330-cAb1.hIgG1(35783) (the parent, hamster anti-TNFRSF25 antibody that was made
5 chimeric with human IgFc), to alanine mutants of WBP330-hPro1.ECD.hFcHis that were expressed at greater than 1500 ng/ml. The binding affinity to each mutein was compared to that of non-mutated WBP330-hPro1.ECD.hFcHis (FIG. 5). Muteins that exhibited a signal change more than 25% (fold change <0.75 ; TABLE 3 and FIG. 6) were used for structure modeling (FIGS. 7 and 8).

10 In addition, studies were conducted to determine whether the antibody could inhibit binding of TL1A to TNFRSF25, and vice versa. As shown in FIG. 9, the binding of an anti-TNFRSF25 antibody ("hamster parental") to recombinant human TNFRSF25 was blocked by TL1A-Ig (left pair of bars). Conversely, binding of the TL1A-Ig fusion to recombinant human TNFRSF25 was blocked by the parental anti-TNFRSF25 antibody
15 (center pair of bars). In addition, the binding of a humanized anti-TNFRSF25 antibody (derived from the "hamster parental" antibody) to recombinant human TNFRSF25 was blocked by TL1A-Ig (right pair of bars).

TABLE 2B

AA#	ng/ml	AA#	ng/ml	AA#	ng/ml	AA#	ng/ml	AA#	ng/ml
99	2770.3	74	1483	63	937.7	33	566.9	154	189
41	2759.8	58	1407.6	51	878.1	121	561.8	NC	189.4
64	2617.6	78	1369.9	55	861.2	91	520		
60	2576.9	67	1360	73	845.5	140	482.6		
47	2515.3	34	1315.4	136	825.2	123	478.8		
84	2513.1	112	1255.8	133	824.7	32	477.5		
54	2431.3	61	1176.1	108	765.3	95	474.6		
97	2401.9	92	1166.2	104	735	117	473.7		
65	2289.6	70	1138.2	138	709.9	116	470.7		
89	2230.1	49	1133.5	35	693.9	130	463.1		
36	2215.5	76	1062.6	107	688.1	148	456.9		
59	2195.3	56	1033.5	50	686.3	106	373.7		
69	2158.1	52	1028.1	120	671	141	370.4		
77	2143.1	71	1024.9	93	668.9	135	326.8		
44	2082.3			115	649.9				
101	2080.7			125	629.3				
102	2017			83	608.1				
109	1811.1								
46	1809.2								
96	1796.5								
79	1788.2								
113	1739.1								
105	1672.4								
66	1661.7								
68	1643.4								
48	1622.4								
134	1562.6								

NC = Negative control (293F cells only)

TABLE 3

Identified epitope	Fold change
G66	0.33
T69	0.37
C65	0.37
P64	0.40
Possible epitope	Fold change
P60	0.54
G44	0.54
A109	0.59
F46	0.62
H84	0.63
K41	0.63
A36	0.65
D96	0.66

Example 2 – Affinity Maturation and Characterization Methods

Affinity optimization of W3153-P8R32-H6 antibody: Each amino acid of the three

5 CDRs of the parental clone was individually mutated to all 20 amino acids using a hybridization mutagenesis method (Kunkel, *Proc Natl Acad Sci USA* 82(2):488-492, 1985). DNA primers containing a NNS codon encoding 20 amino acids were used to introduce mutations at each targeted CDR position. The individual degenerate primers were used in hybridization mutagenesis reactions. Briefly, each degenerate primer was
 10 phosphorylated, then used in a 10:1 ratio with uridinylated ssDNA. The mixture was heated to 85°C for 5 minutes and then cooled down to 55°C over 1 hour. Thereafter, T4 ligase and T4 DNA polymerase were added, and mix was incubated for 1.5 hours at 37°C. Synthesis products for VH and VL CDRs were pooled, respectively. Typically, 200 ng of the pooled library DNA was electroporated into BL21 for plaque formation on a
 15 BL21 bacterial lawn or for production of scFv fragments.

The sequences of the parental heavy and light chains, and their CDR and FW regions, were as follows:

Heavy chain variable region: EVQLVESGGGLSQPGNSLQLSCEASGFTFSNH
DLNWVRQAPGKGLEWVAYISSASGLISYADAVRGRFTISRDNANKNSLFLQMNNL
KSED TAMYYCARDPPYSGLYALDFWGQGTQVTVSS (SEQ ID NO:5)

FW1: EVQLVESGGGLSQPGNSLQLSCEAS (SEQ ID NO:11)

5 CDR1: GFTFSNHDLN (SEQ ID NO:12)

FW2: WVRQAPGKGLEWVA (SEQ ID NO:13)

CDR2: YISSASGLISYADAVRG (SEQ ID NO:14)

FW3: RFTISRDNANKNSLFLQMNNLKSED TAMYYCAR (SEQ ID NO:15)

CDR3: DPPYSGLYALDF (SEQ ID NO:16)

10 FW4: WGQGTQVTVSS (SEQ ID NO:17)

Light chain variable region: QPVLTQSPSASASLSGSKVLTCTLSSELSSYT
IVWYQQRPDKAPKYVMYLKSDGSHSKGDGIPDRFSGSSSGAHRYLSISNVQSED
DATYFCGAGYTLAGQYGWVFGSGTKVTVL (SEQ ID NO:6)

FW1: QPVLTQSPSASASLSGSKVLTCT (SEQ ID NO:18)

15 CDR1: TLSSELSSYTIV (SEQ ID NO:19)

FW2: WYQQRPDKAPKYVMY (SEQ ID NO:20)

CDR2: LKSDGSHSKGD (SEQ ID NO:21)

FW3: GIPDRFSGSSSGAHRYLSISNVQSEDDATYF (SEQ ID NO:22)

CDR3: CGAGYTLAGQYGWV (SEQ ID NO:23)

20 FW4: FGS GTKVTVL (SEQ ID NO:24)

Primary screening of the scFv library: The primary screen consisted of a single point ELISA (SPE) assay, which was carried out using periplasmic extract (PE) of bacteria grown in 96-well (deep well) plates. Briefly, this capture ELISA involved coating individual wells of a 96-well Maxisorp Immunoplate with anti-c-myc antibody in coating buffer (200 mM Na₂CO₃/NaHCO₃) at pH 9.2 overnight at 4°C. The next day, the plate was blocked with Casein for 1 hour at room temperature. scFv PE was then added to the plate and incubated at room temperature for 1 hour. After washing, biotinylated antigen protein was added to the well and the mixture was incubated for 1 hour at room temperature. This was followed by incubation with streptavidin-horseradish peroxidase (HRP) conjugate for 1 hour at room temperature. HRP activity was detected with tetra-

30

5 methyl-benzidine (TMB) substrate, and the reaction was quenched with 2M HCl. Plates were read at 450 nM. Clones exhibiting an optical density (OD) signal at 450 nm that was greater than the OD signal of the parental clone were picked and re-assayed by ELISA (as described above) in duplicate, to confirm positive results. Clones that repeatedly exhibited a signal greater than that of the parental antibody were sequenced. The scFv protein concentration of each clone that had a CDR change was then determined by a quantitative scFv ELISA, where a scFv with known concentration was used as a reference. The scFv protein concentration was determined by comparing the ELISA signals with signals generated by the reference scFv. The binding assay was repeated 10 once more for all positive variants under normalized scFv concentrations in order to determine the relative binding affinity of the mutant scFv and the parental antibody. Selected scFv hits displaying improved binding were re-formulated to IgG1 and tested in a caspase-3 assay as described below.

15 *Combinatorial screening of the scFv library:* Point mutations in the VH and VL chains that were determined to be beneficial for binding to antigen were combined to determine whether additional binding synergy was attained. The combinatorial mutants were expressed as scFv and screened using the capture ELISA. Clones exhibiting an OD signal at 450 nm that was greater than the OD signal of the parental clone were sequenced and further ranked by binding ELISA as described above. Eleven top-ranked clones were selected for IgG4 re-formatting and further characterization as described 20 above.

Reformatting, transient expression, and purification of 4C12 mutants with improved affinity: V-genes of the top-rScFv clones identified from the primary and combinatorial screening were amplified by PCR and cloned into WuXi Biologics' 25 proprietary expression vector, and expressed from 293F cells. Culture supernatants containing the antibodies were harvested and purified using Protein A chromatography.

Caspase release assay: P815 cells expressing TNFRSF25 were incubated with various concentrations of antibodies (from 1 µg/ml to 1 ng/ml) for 5 hours at 37°C in a 96-well plate. Caspase activity was determined using the Homogeneous Caspase Assay

kit (Roche: 005372001). Fluorescence was read using a Molecular Devices SPECTRAMAX® M5e plate reader.

Competition assays: Parental p815 cells and p815 cells expressing human TNFRSF25 (also referred to as p815-hDR3) were cultured in suspension in IMDM + 10% FBS. Cells were counted at the time of harvest, pelleted and resuspended at a concentration of 300,000 cells/100 µL in serum free media. 100 µL aliquots of the cell suspension were placed into Eppendorf tubes.

ALEXA FLUOR® 647 (AF647)-conjugated 4C12 and hTL1A-Ig (AKTA purification, round 1) were generated using a Molecular Probes ALEXA FLUOR® labeling kit (RL# 170512) per the manufacturer's instructions. The degree of labeling for 4C12-AF647 was 5.98 moles of dye to antibody, and for hTL1A-Ig-AF647 the degree of labeling was 4.55 moles of dye to protein (both considered to be within the acceptable range).

hTL1A-Ig-AF647 or 4C12-AF647 was added to the Eppendorf tubes at a concentration of 0.5 µg/mL. Unlabeled 4C12, affinity matured 4C12 (hIgG1 subtype), or isotype control hIgG1 was added immediately afterward at concentrations ranging from 2 µg/mL to 0.0078 µg/mL. The mixtures were as incubated at 37°C in a humidified incubator with 5% CO₂ for 1 hour. Cells were pelleted in a microcentrifuge and washed 1x with FACS buffer. Pellets were resuspended in 300 µL FACS buffer and analyzed by a Sony SH800 flow cytometer. Live single cells were gated on, and MFI for AF647 was determined for each sample.

Example 3 – Affinity Maturation and Characterization Results

Primary screening yielded 11 mutants at 7 CDR positions that showed capture ELISA signal at least 2-fold higher than that of the wild-type (TABLE 4). Multiple mutations at position 42 in the light chain CDR1 consistently showed improved binding to TNFRSF25-Fc protein. Substitution of Ser to Trp at this position resulted in more than a 10-fold increase in ELISA signal. Two other mutations, Ala to Thr at position 27 in the heavy chain CDR3 and Tyr to Phe at position 43 in the light chain CDR1 also showed significant binding improvement. These mutants were converted to IgG1 and tested for

activity using a caspase-3 assay (TABLE 5). Only the mutants at position 42 showed improved potency in the caspase-3 release assay. One particular IgG clone, W3072-z4C12-R1-42G2-uIgG1L, which contains the Ser to Trp mutation in the light chain CDR1, showed the highest increase in caspase-3 agonistic activity.

5

TABLE 4
Primary screening hits

CDR	Sample ID	OD ₄₅₀	Mutation	WT* OD ₄₅₀	BMK [¶] OD ₄₅₀	NC [†] OD ₄₅₀	PC [‡] OD ₄₅₀
VHCDR2	10C3	0.70	A→D	0.28	0.13	0.12	0.35
VHDCR2	12F7	0.85	G→Q	0.26	0.10	0.10	0.41
VHCDR3	27A3	1.61	S→T	0.29	0.12	0.08	0.53
VLCDR1	42F2	0.83	S→G	0.27	0.13	0.09	0.34
	42G2	3.19	S→W	0.27	0.13	0.09	0.34
	42H4	1.21	S→N	0.27	0.13	0.09	0.34
	42H8	1.67	S→Y	0.27	0.13	0.09	0.34
	42F9	2.33	S→F	0.27	0.13	0.09	0.34
	43F11	1.60	Y→F	0.22	0.10	0.09	0.45
VHCDR3	60E8	0.44	A→M	0.11	0.07	0.05	0.16
VHCDR3	66B8	0.40	G→N	0.15	0.07	0.06	0.20

* W3072-z4C12-scFv

¶ W381-1H11-scFv

† Non-specific control

‡ W3072-z4C12 parental clone

10

TABLE 5
Caspase Release Results

Ab	EC50
W3072-z4C12-R1-60H10-uIgG1L	0.085
W3072-z4C12-R1-66B8-uIgG1L	0.071
W330-cAb1.hIgG1 (35783)	0.065
W330-hpro1L1 (TL1A)	~0.334
W330-hAb. 35816	0.115
W3343-P6R31-1B2-uIgG1L	1.771
W3072-z4C12-R1-27A4-uIgG1L	0.142
W3072-z4C12-R1-42F2-uIgG1L	0.057
W3072-z4C12-R1-42G2-uIgG1L	0.018
W3072-z4C12-R1-42H8-uIgG1L	0.032
W3072-z4C12-R1-42F9-uIgG1L	0.043
W3072-z4C12-R1-43F11-uIgG1L	~0.1

5 All individual affinity-improving mutations identified in the primary screening were used to design and construct a combinatorial mutant library. This library was screened to identify combinations of mutations that had synergistic effects on binding improvement. Single mutant clone 42G2 was used as the benchmark. Multiple combination mutant clones with significantly improved binding to TNFRSF25-Fc protein were identified (FIG. 10). However, only one combination mutant, 9G2, included the Ser to Trp mutation in the light chain CDR1. This clone, as well as three additional clones that displayed the strongest binding to TNFRSF25-Fc protein (9A5, 1F10, and 5A6) were selected for IgG conversion and further testing (TABLE 6).

TABLE 6

Well Site	VHCDR3 (SEQ ID)	VLCDR1 (SEQ ID)	VLCDR3 (SEQ ID)	Bmax	Kd
Z4C12	DPFYSGLYALDF (16)	TLSELSSYTIV (19)	CGAGYTLAQYGVV (23)	0.1002	0.00008994
42G2 (16)W.... (25) (23)	0.4468	0.03675
9A5	..A.T..... (26)GF.... (27)N..... (28)	1.811	0.07688
1F10	..A.T..... (26)NF.... (29)S..... (30)	1.731	0.1177
10B8	..A..... (31)NF.... (29) (23)	1.486	0.1621
5A6	...T..... (32)NF.... (29)N..... (28)	1.887	0.1602
4B6	..A.T..... (26)N.... (33)N..... (28)	1.263	0.1488
3G4	..A.T..... (26)GF.... (27)R..... (34)	1.527	0.1464
2A5	..A.T..... (26)NF.... (29)	..M.....N..... (35)	1.282	0.09108
5E1	..A.T..... (26)N.... (33)	..M.....N..... (35)	1.322	0.1303
6G11 (16)NF.... (29) (23)	1.325	0.1172
9G2	..A.T..... (26)W.... (25) (23)	1.038	0.05068

After IgG conversion, clones with improved binding to the TNFRSF25-Fc protein were designated as follows:

1F10 → W3072-z4C12-m1 (also referred to herein as M1)

5A6 → W3072-z4C12-m2 (also referred to herein as M2)

5 9A5 → W3072-z4C12-m3 (also referred to herein as M3)

9G2 → W3072-z4C12-m4 (also referred to herein as M4)

42G2 → W3072-z4C12-m5 (also referred to herein as M5)

Caspase-3 release assays revealed that only M5 and M4 (both containing the Ser→Trp substitution in the light chain CDR1) showed improved agonistic activity as compared to the parental humanized clone (W330-hAb35816, generated by CDR grafting) and the natural ligand TL1A, while three other mutants showed inferior agonistic activity (FIGS. 11A and 11B, TABLE 6) but higher affinity binding to TNFRSF25 than the parent antibody (FIG. 10). Interestingly, the M4 higher affinity clone had a higher amplitude of response than the M5 clone (FIG. 11B). The highest affinity clone, M3, had agonist activity that was inferior to that of the parental humanized antibody and the chimeric clone (FIG 11A). It also was surprising that humanized parent had a markedly superior amplitude of response as compared to the chimeric parent antibody (FIG. 11A).

M5 and M4 were reformatted to IgG4, and the IgG1 and IgG4 formats were both tested in the caspase-3 release assay. These studies revealed that the IgG1 formatted antibodies consistently showing improved agonistic activity as compared to the parental humanized 4C12 IgG1 (W330-hAb35816; TABLE 7).

TABLE 7

Ab	EC50
W330-cAb1.hIgG1 (35783)	0.088
W330-hproL1 (TL1A)	0.706
W330-hAb.35816	0.095
W3343-P6R31-1B2-uIgG1L	NA
M1-uIgG1L	1.839
M2-uIgG1L	0.656
M3-uIgG1L	0.17
M4-uIgG1L	0.07
M5-uIgG1L	0.08
M4-uIgG4L	0.1
M5-uIgG4L	0.1

Competition studies were conducted to determine whether the affinity matured antibodies could compete with 4C12 or TL1A for binding to TNFRSF25. In a first experiment, all samples received 0.5 µg/mL hTL1A-Ig-AF647, which was competed off with unlabeled 4C12-M3, 4C12-M4, 4C12-M5, and 4C12. As indicated in FIG. 13A, the M4 and M5 antibodies demonstrated stronger competition against TL1A than the 4C12 parent antibody. Thus, although M4 and M5 showed weaker binding to TNFRSF25-Fc than M3 (9A5; FIG. 10) but stronger binding than the parent antibody (WT; FIG. 10), they appeared to be stronger competitors of TL1A binding to cell surface-expressed TNFRSF25. Samples receiving no hTL1A-Ig-AF647 had a MFI of about 1000, and samples receiving hIgG1 isotype had an MFI of about 3320.

Further competition assays were conducted in which all samples received 0.5 µg/mL 4C12-AF647, which was competed off with unlabeled 4C12-M3, 4C12-M4, and 4C12-M5 at extended unlabeled antibody concentrations up to 8 µg/mL to complete the binding curve. As indicated in FIG. 13B, unlabeled 4C12 parent competed off labeled 4C12, while isotype hIgG1 had no competitive effect. Samples receiving no 4C12-AF647 had an MFI of about 1400. The 4C12, M4, and M5 affinity matured antibodies demonstrated similar competition against labeled 4C12, while M3 was the weakest competitive inhibitor.

Thus, when humanized 4C12 antibody was affinity matured, primary screening (by saturated mutagenesis of antibody CDRs) identified multiple mutants with improved binding to TNFRSF25-Fc protein. In particular, clone M5 containing a

Ser→Trp mutation in the light chain CDR1 showed improved agonistic activity as determined by caspase-3 release assay. Combinatorial library screening yielded multiple mutants with significantly stronger binding than M5 to a TNFRSF25-Fc protein, but surprisingly, most of these displayed inferior agonistic activity as compared to the parental antibody. The exception to this was M4, which contained the same Ser→Trp mutation in the light chain CDR1 as M5. Only M5 and M4 showed both improved agonistic activity in the caspase-3 release assay and improved binding to the TNFRSF25-Fc fusion protein. In addition, these clones also displayed stronger competition binding against TL1A to cellularly-expressed TNFRSF25 as compared to the 4C12 parent (FIG. 13A) while maintaining comparable competition against 4C12 binding to TNFRSF25 (FIG. 13B).

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. An anti-TNFRSF25 antibody or antigen binding fragment thereof, wherein the antibody or antibody fragment comprises:
 - (i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSNHDLN (SEQ ID NO:12), the heavy chain CDR2 sequence is YISSASGLISYADAVRG (SEQ ID NO:14); and the heavy chain CDR3 sequence is DPAYTGLYALDF (SEQ ID NO:26) or DPPYSGLYALDF (SEQ ID NO:16); and
 - (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is TLSSELSWYTIV (SEQ ID NO:25), the light chain CDR2 sequence is LKSDGSHSKGD (SEQ ID NO:21), and the light chain CDR3 sequence is CGAGYTLAGQYGWV (SEQ ID NO:23).
2. The antibody or antigen binding fragment of claim 1, further comprising variable region framework (FW) sequences juxtaposed between the CDRs according to the formula (FW1)-(CDR1)-(FW2)-(CDR2)-(FW3)-(CDR3)-(FW4), wherein the variable region FW sequences in the heavy chain variable region are heavy chain variable region FW sequences, and wherein the variable region FW sequences in the light chain variable region are light chain variable region FW sequences.
3. The antibody or antigen binding fragment of claim 2, wherein the variable region FW sequences are human.
4. The antibody or antigen binding fragment of any one of claims 1 to 3, further comprising human heavy chain and light chain constant regions.
5. The antibody or antigen binding fragment of claim 4, wherein the constant regions are selected from the group consisting of human IgG1, IgG2, IgG3, and IgG4.
6. The antibody or antigen binding fragment of claim 5, wherein the constant regions are IgG1.
7. The antibody or antigen binding fragment of claim 4, wherein the constant regions are IgG4.

8. The antibody or antigen binding fragment of any one of claims 1 to 7, wherein tumor cell apoptosis in a subject is increased following administration of the antibody or antigen binding fragment to the subject at a dose of about 0.1 mg/kg to about 50 mg/kg.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the antibody or antigen binding fragment of any one of claims 1 to 8.
10. An article of manufacture comprising the pharmaceutical composition of claim 9 and at least one additional agent for treating cancer.
11. The article of manufacture of claim 10, wherein the at least one additional agent is an agent that targets CTLA-4, PD-1, PD-L1, LAG-3, Tim-3, TNFRSF4, TNFRSF9, TNFRSF18, CD27, CD39, CD47, CD73, or CD278, or is an A2A receptor antagonist or a TGF-beta antagonist.
12. The article of manufacture of claim 10, wherein the at least one additional agent is a B7 family costimulatory molecule, a TNF receptor superfamily costimulatory molecule, a vaccine composition, or a chemotherapeutic agent.
13. The article of manufacture of claim 10, wherein the at least one additional agent comprises chimeric antigen receptor-transfected T cells or expanded tumor infiltrating lymphocytes for use in an adoptive T cell therapy *in vitro* or in a subject.
14. The article of manufacture of claim 10, wherein the at least one additional agent is used during the *in vitro* manufacturing process of an autologous T cell therapy.
15. A method for treating a tumor in a subject, comprising administering to the subject an amount of the composition of claim 9 that is effective to induce apoptosis of TNFRSF25-expressing tumor cells in the tumor.
16. A method for stimulating proliferation of CD8⁺ T cells in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 9.

17. The method of claim 16, wherein proliferation of CD8⁺ T cells is increased by at least about 20% as compared to the baseline level of proliferation prior to the administering, as determined by flow cytometry analysis of antigen specific CD8⁺ T cells.
18. A method of eliciting an immune response in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 9.
19. A method for stimulating proliferation of CD4⁺FoxP3⁺ regulatory T cells in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 9.
20. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody or Fab fragment thereof, upon binding to TNFRSF25, elicits a signaling event that is consistent with a signaling event elicited by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids C48-L71 of human TNFRSF25.
21. The isolated monoclonal antibody or Fab fragment of claim 20, wherein the antibody or fragment binds to an epitope containing at least one of the following residues of TNFRSF25: C48, R49, G50, C51, P52, A53, G54, H55, Y56, L57, K58, A59, P60, C61, T62, E63, P64, C65, G66, N67, S68, T69, C70, or L71 of SEQ ID NO:1.
22. The isolated monoclonal antibody or Fab fragment of claim 20, wherein binding of the antibody or fragment to TNFRSF25 blocks binding of TL1A to TNFRSF25.
23. The isolated monoclonal antibody or Fab fragment of claim 20, wherein the antibody is a humanized antibody.
24. The isolated monoclonal antibody or Fab fragment of claim 20, wherein the antibody is a human antibody.

25. The isolated monoclonal antibody or Fab fragment of claim 20, wherein the antibody is an IgG antibody.
26. The isolated monoclonal antibody or Fab fragment of claim 20, wherein the antibody or fragment is capable of binding to mouse TNFRSF25 and human TNFRSF25 with K_d values within 100-fold of the other.
27. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody or Fab fragment thereof, upon binding to TNFRSF25, elicits a signaling event that is characteristic of a signaling event elicited by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids P64-T69 of human TNFRSF25.
28. The isolated monoclonal antibody or Fab fragment of claim 27, wherein the antibody or fragment binds to an epitope containing at least one of the following residues of TNFRSF25: P64, C65, G66, N67, S68, or T69 of SEQ ID NO:1.
29. The isolated monoclonal antibody or Fab fragment of claim 27, wherein binding of the antibody or fragment to TNFRSF25 blocks binding of TL1A to TNFRSF25.
30. The isolated monoclonal antibody or Fab fragment of claim 27, wherein the antibody is a humanized antibody.
31. The isolated monoclonal antibody or Fab fragment of claim 27, wherein the antibody is a human antibody.
32. The isolated monoclonal antibody or Fab fragment of claim 27, wherein the antibody is an IgG antibody.
33. The isolated monoclonal antibody or Fab fragment of claim 27, wherein the antibody or fragment is capable of binding to mouse TNFRSF25 and human TNFRSF25 with K_d values within 100-fold of the other.

34. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having a sequence at least 80% identical to the sequence set forth in C48-L71 of SEQ ID NO:1.
35. The isolated monoclonal antibody or fragment of claim 34, wherein the antibody binds to an epitope having a sequence at least 90% identical to the sequence set forth in C48-L71 of SEQ ID NO:1.
36. The isolated monoclonal antibody or fragment of claim 34, wherein the antibody binds to an epitope having a sequence at least 95% identical to the sequence set forth in C48-L71 of SEQ ID NO:1.
37. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having a sequence at least 85% identical to the sequence set forth in P64-T69 of SEQ ID NO:1.
38. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with four or fewer amino acid substitutions.
39. The isolated monoclonal antibody or Fab fragment of claim 38, wherein the antibody binds to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with three or fewer amino acid substitutions.
40. The isolated monoclonal antibody or Fab fragment of claim 38, wherein the antibody binds to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with two or fewer amino acid substitutions.
41. The isolated monoclonal antibody or Fab fragment of claim 38, wherein the antibody binds to an epitope having the sequence set forth in C48-L71 of SEQ ID NO:1, but with one amino acid substitution.
42. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody binds to an epitope having the sequence set forth in P64-T69 of SEQ ID NO:1, but with one amino acid substitution.

43. A method for inhibiting tumor growth in a mammal, comprising administering to the mammal a composition comprising a pharmaceutically acceptable carrier and a monoclonal antibody, or an Fab fragment thereof, that binds specifically to human TNFRSF25, wherein the antibody or Fab fragment thereof is capable of mimicking a signaling event stimulated by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids C48-L71 of human TNFRSF25.
44. The method of claim 43, wherein the antibody or fragment binds to an epitope containing at least one of the following residues of TNFRSF25: C48, R49, G50, C51, P52, A53, G54, H55, Y56, L57, K58, A59, P60, C61, T62, E63, P64, C65, G66, N67, S68, T69, C70, or L71 of SEQ ID NO:1.
45. The method of claim 43, wherein the antibody or fragment binds to an epitope containing at least one of the following residues of TNFRSF25: P64, C65, G66, N67, S68, or T69 of SEQ ID NO:1.
46. The method of claim 43, wherein binding of the antibody or fragment to TNFRSF25 blocks binding of TL1A to TNFRSF25.
47. The method of claim 43, wherein the antibody is a humanized antibody.
48. The method of claim 43, wherein the antibody is a human antibody.
49. The method of claim 43, wherein the antibody is an IgG antibody.
50. The method of claim 43, wherein the antibody or fragment is capable of binding to mouse TNFRSF25 and human TNFRSF25 with K_a values within 100-fold of the other.
51. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated monoclonal antibody or Fab fragment of claim 20, claim 27, claim 34, claim 37, claim 38, or claim 42.
52. Use of the pharmaceutical composition of claim 51 for treating cancer in a patient.

FIG. 1A

TNFRSF25	1QGG <u>TR</u> SPRCDACGDF <u>HK</u> KI <u>GL</u> <u>FCC</u> RRGCPAG <u>HY</u> LKAP <u>CTE</u> P <u>CG</u> NST <u>CL</u> V <u>C</u>
TNFR1	1	Y <u>PS</u> G <u>V</u> I <u>GL</u> V <u>PH</u> L <u>G</u> D <u>RE</u> <u>KR</u> D <u>SV</u> C <u>P</u> <u>Q</u> <u>G</u> K <u>Y</u> I <u>H</u> <u>P</u> QNN <u>SI</u> <u>C</u> <u>CT</u> <u>K</u> <u>HK</u> <u>G</u> <u>F</u> <u>Y</u> L <u>Y</u> N <u>DC</u> P <u>G</u> <u>Q</u> D <u>T</u> <u>D</u> <u>C</u> <u>RE</u> <u>C</u>
Fas	1	RL <u>SS</u> .KSVNAQ <u>VT</u> <u>D</u> IN <u>SK</u> GLE <u>LR</u> K <u>T</u> <u>VT</u> <u>T</u> <u>VE</u> <u>T</u> <u>Q</u> N <u>LE</u> GL <u>HD</u> <u>G</u> <u>F</u> <u>CH</u> K <u>P</u> <u>CP</u> <u>GER</u> KAR <u>DC</u> T <u>V</u> N <u>DE</u> P <u>DC</u> V <u>PC</u>
		<div>I</div>
TNFRSF25	50	PQDT <u>FL</u> <u>AW</u> ENHHN <u>SE</u> CAR <u>Q</u> OA <u>CDE</u> QA <u>SQ</u> VA <u>ENC</u> SA <u>VA</u> D <u>TR</u> CGCK <u>P</u> G <u>WE</u> VC <u>Q</u> VS <u>SS</u> SP <u>FY</u> C <u>Q</u> PC <u>LD</u>
TNFR1	63	ES <u>GS</u> <u>FT</u> <u>A</u> <u>SEN</u> HL. <u>RH</u> <u>CL</u> <u>S</u> <u>CS</u> K <u>CK</u> EM <u>GQ</u> VE <u>IS</u> <u>CT</u> V <u>DR</u> D <u>T</u> <u>VC</u> GR <u>KN</u> <u>Q</u> Y <u>RH</u> W <u>SEN</u> L..... <u>FQ</u> <u>C</u> <u>FN</u> <u>CS</u> L
Fas	70	QEG <u>KE</u> Y <u>TD</u> KA <u>H</u> <u>F</u> <u>S</u> K <u>CR</u> <u>RC</u> <u>RL</u> <u>CDE</u> GH <u>VE</u> I <u>NC</u> T <u>RT</u> Q <u>NT</u> <u>K</u> <u>CR</u> <u>CK</u> <u>PN</u> <u>FF</u> .. <u>CN</u> <u>ST</u> V <u>C</u> <u>EH</u> <u>CD</u> <u>PC</u> <u>TK</u>
		<div>II</div>
TNFRSF25	120	CGAL <u>HR</u> H <u>TR</u> L <u>CS</u> .RRD <u>TD</u> CG <u>TC</u> LL <u>GE</u> Y <u>EH</u> GD <u>GC</u> V <u>SC</u> PT <u>ST</u> LG <u>SC</u> PE.. <u>RCA</u> <u>AV</u> <u>C</u> .. <u>GWR</u> <u>Q</u> <u>MF</u> <u>W</u> <u>V</u> <u>Q</u>
TNFR1	127	<u>C</u> .. <u>L</u> <u>NG</u> <u>TV</u> <u>HL</u> <u>SC</u> QEK <u>Q</u> <u>NT</u> <u>VC</u> . <u>TC</u> <u>H</u> <u>AG</u> <u>F</u> <u>FL</u> RE <u>NE</u> <u>CV</u> <u>SC</u> <u>SN</u> <u>CK</u> <u>S</u> <u>LE</u> <u>CT</u> <u>KL</u> <u>CL</u> PQI <u>EN</u> V <u>K</u> GT <u>ED</u> <u>SG</u> <u>T</u>
Fas	133	<u>C</u> .. <u>EH</u> <u>GI</u> <u>IK</u> <u>EC</u> <u>T</u> <u>LT</u> <u>S</u> <u>NT</u> <u>K</u> <u>C</u> .KEEG <u>SR</u> <u>SN</u>
		<div>III</div>
TNFRSF25	181	VLL <u>AG</u> <u>LV</u> <u>PL</u> LL <u>G</u> AT <u>LT</u> <u>TY</u> <u>RHC</u> . <u>W</u> . <u>PH</u> K <u>PL</u> <u>V</u> <u>TA</u> DEAG <u>ME</u> ALT <u>PP</u> <u>PA</u> <u>TH</u> <u>LS</u> <u>PL</u> <u>DS</u> A <u>HT</u> <u>LL</u> <u>AP</u> <u>PD</u> <u>SS</u>
TNFR1	189	TVLL <u>PL</u> <u>V</u> I <u>FF</u> <u>GL</u> <u>CL</u> LL <u>SL</u> FI <u>GL</u> <u>MY</u> <u>R</u> <u>Q</u> <u>FW</u> <u>KS</u> <u>K</u> <u>LY</u> <u>S</u> <u>IV</u> <u>CG</u> <u>K</u> <u>ST</u> <u>PE</u> <u>KE</u> <u>GE</u> <u>LE</u> <u>GT</u> <u>TK</u> <u>PL</u> <u>AP</u> <u>NP</u> <u>S</u> <u>FS</u> <u>PT</u> <u>PG</u> <u>FT</u>
Fas	158	.. <u>LG</u> <u>WL</u> <u>CL</u> LL <u>PI</u> <u>LV</u> <u>W</u> <u>KR</u> <u>KE</u> <u>V</u> <u>Q</u> <u>K</u> <u>CR</u> <u>K</u> <u>R</u> <u>KE</u> <u>N</u> <u>Q</u> <u>GS</u> <u>HE</u>
		<div>TM</div>
TNFRSF25	245	E <u>K</u> I <u>CT</u> <u>V</u> <u>Q</u> <u>L</u> <u>V</u> <u>GN</u> <u>SW</u> <u>TP</u> <u>G</u> <u>Y</u> <u>PE</u> <u>T</u> <u>Q</u> <u>E</u> <u>AL</u> <u>CP</u> <u>Q</u> <u>V</u> <u>T</u> <u>W</u> <u>SD</u> <u>Q</u> <u>L</u> <u>PS</u> <u>R</u> <u>AL</u> <u>G</u> <u>P</u> <u>AA</u> .. <u>APT</u> <u>LS</u> <u>P</u> <u>ES</u> <u>P</u> <u>AG</u> <u>SP</u> <u>AM</u> <u>ML</u> <u>Q</u> <u>P</u>
TNFR1	259	PTL <u>G</u> <u>F</u> <u>SP</u> <u>VP</u> <u>SS</u> <u>T</u> <u>FT</u> <u>SS</u> <u>TY</u> <u>TP</u> <u>GD</u> . <u>CE</u> <u>N</u> <u>FA</u> <u>AP</u> <u>RR</u> <u>EV</u> <u>AP</u> <u>P</u> <u>Y</u> <u>Q</u> <u>G</u> <u>AD</u> <u>P</u> <u>IL</u> <u>ATA</u> <u>LA</u> <u>SD</u> <u>PI</u> <u>PN</u> <u>L</u> <u>Q</u> <u>K</u> <u>W</u> <u>ED</u> <u>SA</u> <u>HK</u> <u>P</u> <u>Q</u>
Fas	196 <u>SPT</u> <u>LN</u> <u>PE</u> <u>TV</u> <u>A</u> <u>IN</u> <u>L</u> <u>SD</u> <u>VD</u> <u>L</u>
		<div>DD</div>
TNFRSF25	308 <u>GP</u> <u>Q</u> <u>LY</u> <u>D</u> <u>V</u> <u>MD</u> <u>AV</u> <u>PAR</u> <u>R</u> <u>WK</u> <u>E</u> <u>F</u> <u>VR</u> <u>TL</u> <u>GL</u> <u>RE</u> <u>AE</u> <u>I</u> <u>E</u> <u>AV</u> <u>E</u> <u>VE</u> <u>I</u> <u>GR</u> . <u>FR</u> <u>D</u> <u>Q</u> <u>Y</u> <u>EM</u> <u>L</u> <u>K</u> <u>R</u> <u>WR</u> <u>Q</u> <u>Q</u> <u>P</u> <u>AG</u> <u>L</u> <u>G</u> ...
TNFR1	328	SLD <u>T</u> <u>DD</u> <u>P</u> <u>AT</u> <u>LY</u> <u>AV</u> <u>EN</u> <u>VP</u> <u>PL</u> <u>R</u> <u>WK</u> <u>E</u> <u>F</u> <u>VR</u> <u>RL</u> <u>GL</u> <u>SD</u> <u>HE</u> <u>ID</u> <u>RL</u> <u>EL</u> <u>Q</u> <u>NG</u> <u>R</u> <u>CL</u> <u>RE</u> <u>AY</u> <u>S</u> <u>ML</u> <u>AT</u> <u>WR</u> <u>RR</u> <u>TP</u> <u>RR</u> <u>E</u> <u>AT</u> <u>LE</u>
Fas	214 <u>SK</u> <u>Y</u> <u>IT</u> <u>T</u> <u>I</u> <u>AG</u> <u>VM</u> <u>T</u> <u>LS</u> <u>Q</u> <u>V</u> <u>K</u> <u>G</u> <u>F</u> <u>VR</u> <u>K</u> <u>NG</u> <u>V</u> <u>NE</u> <u>A</u> <u>K</u> <u>IDE</u> <u>I</u> <u>K</u> <u>ND</u> <u>N</u> <u>V</u> <u>Q</u> <u>DT</u> <u>AE</u> <u>Q</u> <u>V</u> <u>Q</u> <u>L</u> <u>LR</u> <u>N</u> <u>W</u> <u>H</u> <u>Q</u> <u>L</u> <u>H</u> <u>G</u> <u>K</u> <u>KE</u> <u>A</u> . <u>YD</u>
TNFRSF25	368	AVYAA <u>LER</u> <u>M</u> <u>GL</u> <u>D</u> <u>GC</u> <u>VE</u> <u>D</u> <u>LR</u> <u>S</u> <u>R</u> <u>L</u> <u>Q</u> <u>R</u> <u>GP</u> (SEQ ID NO:2)
TNFR1	398	LL <u>GR</u> <u>VR</u> <u>LD</u> <u>MD</u> <u>LL</u> <u>GC</u> <u>LE</u> <u>IE</u> <u>EA</u> <u>LC</u> <u>G</u> <u>PA</u> <u>AL</u> <u>P</u> <u>P</u> <u>AS</u> <u>LL</u> <u>RR</u> (SEQ ID NO:3)
Fas	277	TL <u>IK</u> <u>DL</u> <u>KK</u> <u>AN</u> <u>LC</u> <u>T</u> <u>LA</u> <u>E</u> <u>K</u> <u>IQ</u> <u>T</u> <u>I</u> <u>IL</u> <u>K</u> <u>D</u> <u>TS</u> <u>D</u> <u>SEN</u> <u>S</u> <u>N</u> <u>FR</u> <u>NE</u> <u>I</u> <u>Q</u> <u>SLV</u> (SEQ ID NO:4)

FIG. 1B

Human TNFRSF25 Sequence 1

Bodmer et al, Immunity 1997

MEQRPARGCAAVAAALLLVLLGARAQGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAW
ENHHNSECARCOACDEQASQVALENCASAVADTRCGCKPGWFVEQVSOQVSSSPFYCQPCLDGALHRHTRLLCSRRDTC
GTCLPGFYEHGDCVSCPTSTLGSCPERCAAVCGWROMFWVQVLLAGLVVPLLGGATLTITYTYRHCWPHKPLVTADAEAGMEA
LTPPPATHLSPLDSAHTLLAPPDSSEKICTVQLVGNWSWTPGYPETQEALCPQVTWSWDQLPSRALGPAAAPTLSPEPAGS
PAMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQOYEMLKRWRRQQPAGLGAVYAALERMGLDGC
VEDLRSLRQGRP (SEQ ID NO:1)

Human TNFRSF25 Sequence 2

>gi|23200021|ref|NP_683866.1| tumor necrosis factor receptor superfamily member 25 isoform 1 precursor [Homo sapiens]

MEQRPARGCAAVAAALLLVLLGARAQGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAW
ENHHNSECARCOACDEQASQVALENCASAVADTRCGCKPGWFVEQVSOQVSSSPFYCQPCLDGALHRHTRLLCSRRDTC
GTCLPGFYEHGDCVSCPTSTLGSCPERCAAVCGWROMFWVQVLLAGLVVPLLGGATLTITYTYRHCWPHKPLV
TADAEAGMEALTTPPPATHLSPLDSAHTLLAPPDSSEKICTVQLVGNWSWTPGYPETQEALCPQVTWSWDQLPSRALGPAAAPT
LSPEPAGSPAMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQOYEMLKRWRRQQPAGLGAVYAA
LERMGLDGCVEDLRSLRQGRP (SEQ ID NO:7)

Mouse TNFRSF25 Sequence

>uc008vzk.1 (Tnfrsf25) length=387

MEELPRRERSPPGAATPGSTARVLQPLFLPLLLLLLLLLLGGQGGMSGRCDCASESQKRYGPFCCRGCPKGHYMKAPCAE
PCGNSTCLPCPSDTFLTRDNHFKTDCTRCQVCDDEALQVTLNCSAKSDTHCGCQSGWCVDCTEPCGKSSPFSVCVPCGAT
TPVHEAPTFLFWVQVLLGVAFLEFGAILICAYCRWQPCAVVTADTAGTETLASPQTAHLSASDSAHTLLAPPSSSTGKICTT
VQLVGNWNTPLGSLQTEVVCQASQPWDQLPNRTLGTPLASPLSPAPPAGSPAVALQPGPQLYDVMDAVPARRWKEFVRTL
GLREAEIEAVEVEICRFRDQOYEMLKRWRRQQPAGLGAIYAALERMGLEGAEDLRSLRQGRP (SEQ ID NO:8)

Rhesus Macaque TNFRSF25 Sequence

>gi|966914523|ref|XP_014998005.1| tumor necrosis factor receptor superfamily member 25 isoform X1 [Macaca mulatta]

MEQRSRGSAAVAAVSTALLLVLLGARAQGGTQSPRCDCAGDFHKKNGVFCCRGCPAGHYLKAPCTEPCGNSTCLLCPQDTFLAW
ENHHNSECARCOACDEQASQVALENCASAVADTRCGCKPGWFVEQVSOQVSSSPFYCQPCLDGALHRHTRLLCSRRDTC
TDCGTCLPGFYEHDDGCVSCPTSTLGSCPERCAAVCGWROMFWVQVLLAGLVVPLLGGATLTITYTYRHCWPHKPMVTADAEAG
MEALTTPPPATHLSPSDKAHTLLVPPDSSEKICTVQLVDNSWTPGYPHTQEALCPQMTWSWDQLPNRALGPVPASTLLPESP
VGSPTMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQOYEMLKRWRRQQPAGLGAVYAALERMGL
DGCAEDLRSLRQGRP (SEQ ID NO:9)

Cynomolgus Macaque TNFRSF25 Sequence

>gi|544409321|ref|XP_005544974.1| PREDICTED: tumor necrosis factor receptor superfamily member 25 isoform X2 [Macaca fascicularis]

MEQRSRGSAAVAAALLLVLLGARAQGGTQSPRCDCAGDFHKKNGVFCCRGCPAGHYLKAPCTEPCGNSTCLLCPQDTFLAW
ENHHNSECARCOACDEQASQVALENCASAVADTRCGCKPGWFVEQVSOQVSSSPFYCQPCLDGALHRHTRLLCSRRDTC
GTCLPGFYEHDDGCVSCPTSTLGSCPERCAAVCGWROMFWVQVLLAGLVVPLLGGATLTITYTYRHCWPHKPMVTADAEAGMEA
LTPPPATHLSPSDNAHTLLVPPDSSEKICTVQLVDNSWTPGYPHTQEALCPQMTWSWDQLPNRALGPVPASTLLPESPVGS
PTMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQOYEMLKRWRRQQPAGLGAVYAALERMGLDGC
AEDLRSLRQGRP (SEQ ID NO:10)

Underlined = Signal Peptide

Highlighted = Extracellular Domain

Bold = Transmembrane Domain

Double Underlined = PTX25 Epitope

FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 11B




FIG. 13A





FIG. 13B



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/036817

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/081455 A1 (PELICAN THERAPEUTICS INC [US]) 26 May 2016 (2016-05-26) cited in the application examples 1-8; sequences 4, 6, 8, 11, 13, 15	1-19
A	----- B.-S. KIM ET AL: "Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease", BLOOD, vol. 126, no. 4, 23 July 2015 (2015-07-23) , pages 546-557, XP055399514, US ISSN: 0006-4971, DOI: 10.1182/blood-2015-04-637587 the whole document ----- -/--	1-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 August 2017

Date of mailing of the international search report

27/10/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Cilensek, Zoran

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2017/036817

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/017303 A1 (UNIV MIAMI [US]; PODACK ECKHARD R [US]; SCHREIBER TAYLOR [US]; WOLF DI) 10 February 2011 (2011-02-10) paragraphs [0104], [0114], [0141]; table 2 -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2017/036817

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-19

An anti-TNFRSF25 antibody or antigen binding fragment thereof, wherein the antibody or antibody fragment comprises:

- (i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSNHDLN (SEQ ID NO:12), the heavy chain CDR2 sequence is YISSASGLISYADAVRG (SEQ ID NO: 14); and the heavy chain CDR3 sequence is DPAYTGLYALDF (SEQ ID NO:26) or DPPYSGLYALDF (SEQ ID NO: 16); and
- (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is TLSSELSWYTIV (SEQ ID NO:25). the light chain CDR2 sequence is LKSDGSHSKGD (SEQ ID NO:21), and the light chain CDR3 sequence is CGAGYTLAQYGWV (SEQ ID NO:23).

2. claims: 20-52

20. An isolated monoclonal antibody, or an Fab fragment thereof, that specifically binds to human TNFRSF25, wherein the antibody or Fab fragment thereof, upon binding to TNFRSF25, elicits a signaling event that is consistent with a signaling event elicited by TL1A binding to TNFRSF25, and wherein the antibody binds to an epitope in the region of amino acids C48-L71, or P64-T69 of human TNFRSF25, or an epitope being at least or 85% identical thereto.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/036817

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016081455	A1	26-05-2016	NONE

WO 2011017303	A1	10-02-2011	AU 2010279637 A1 15-03-2012
			CA 2806840 A1 10-02-2011
			CN 102770455 A 07-11-2012
			DK 2462165 T3 29-08-2016
			EP 2462165 A1 13-06-2012
			ES 2586837 T3 19-10-2016
			IL 217871 A 31-05-2016
			JP 2013501057 A 10-01-2013
			KR 20120089259 A 09-08-2012
			SG 178125 A1 29-03-2012
			SG 10201502330T A 28-05-2015
			US 2012135011 A1 31-05-2012
			US 2017226218 A1 10-08-2017
			WO 2011017303 A1 10-02-2011
